++
++
+++
HISTORY AND EPIDEMIOLOGY
++
Carbon monoxide (CO) is formed during the incomplete combustion of virtually any carbon-containing compound. Because it is an odorless, colorless, and tasteless gas, it is remarkably difficult to detect in the environment even when present at high ambient concentrations and is a leading cause of poisoning morbidity and mortality in the United States. Based on US national death certificate data, there were 439 annual deaths from unintentional non-fire exposure to CO from 1999 to 2004.27 The groups with the highest risk were male gender and elderly age, possibly because of occupational exposure and inability to discern CO symptoms, respectively. The CO-related mortality rate has remained essentially unchanged over the years despite increased CO detector use.22,26,28 More than half of these cases (64%) occurred in homes with faulty furnaces, usually in the fall or winter months. Many clusters were associated with power failures during catastrophic weather, such as ice storms, blizzards, and hurricanes.24,25 Analysis of the Centers for Disease Control and Prevention wide-ranging online data for epidemiologic research (WONDER) database showed total non–fire-related CO poisoning deaths decreased from 1,967 in 1999 to 1,319 in 2014.88 Of these non–fire-related deaths, unintentional cases continue at a rate of approximately 450 annually from 1999 to 2015.29,187
++
Just as important as mortality rates are the greater number of survivors from CO poisoning. Despite increased awareness for CO poisoning, there were still an average of 20,636 nonfatal, unintentional, non–fire-related CO exposures treated annually in the United States.28 More than 40% of cases occurred in the winter, with almost 75% occurring in residences. However, exclusion of intentional and fire-related cases severely underestimates the extent of the problem. Based on firsthand hospital data, a minimum of 50,000 patients with CO poisoning present to US emergency departments (EDs) each year, up to half resulting in hospitalization.96,111 More recent data using probable and suspected cases suggest that there were more than 230,000 ED visits in 2007 alone that were unintentional and related to non-fire CO poisoning.112
++
The bigger problem with CO poisoning is the associated morbidity that survivors risk even after acute treatment. The most serious complication is persistent or delayed neurologic sequelae (DNS) or delayed neurocognitive sequelae, which occurs in up to 50% of patients with symptomatic acute poisonings.81,174,226 At 1 year after exposure, of the 1,643 patients not treated with HBO 42% had cognitive sequellae at 6 weeks, 30% at 6 months and 18% at 12 months. Of the 75 treated with HBO 24% had cognitive sequellae at 6 weeks, 17% at 6 months and 14% at 12 months.228 There is still no highly reliable method of predicting who will have a poor outcome, requiring the threshold for HBO therapy for CO poisoning and follow-up be particularly low.
++
Potential sources of CO abound in our society, often resulting in unintentional poisoning28 (Table 122–1). Although CO is found naturally in the body as a byproduct of hemoglobin degradation by heme oxygenase found in the liver and spleen,47 it is readily available for inhalation from the incomplete combustion of virtually any carbonaceous fuel. Alternatively, absorption (dermal, ingestion, or inhalation) of methylene chloride results in CO toxicity after hepatic metabolism (Chap. 105).156 Despite catalytic converters and other emission controls, more than 50% of unintentional CO deaths are still caused by motor vehicle exhaust.45,151 The introduction of catalytic converters with emissions controls is associated with a decrease in suicide attempts and deaths using automobile exhaust.91 Occupants of motor vehicles are not the only victims of exhaust gases; CO poisoning is also reported in occupants of the beds of pickup trucks and on boats.22,95,130 Workers are at risk from use of propane-powered equipment indoors such as ice skating rink resurfacers21,52 and forklifts.66,104 For optimal performance, propane-powered forklifts are typically adjusted to produce less than 10,000 ppm of CO in exhaust but in fact average more than 30,000 ppm, which could lead to unsafe concentrations in an enclosed warehouse within 1 hour.67
++
++
In the past 10 years, nonvehicular sources of CO have increasingly accounted for the majority of unintentional poisonings.151 More than one-third of the deaths from unintentional CO poisoning occur in winter months (December, January, and February) in the US.29 Predominantly, these involve the burning of charcoal, wood, or natural gas for heating and cooking.92 Furnaces that burn natural gas (methane or propane) for heating are often implicated, especially when the flue is blocked.100,101 Gas kitchen stoves are also an important source of CO in indigent populations with marginal heating systems.101 In fact, the use of gas stoves for supplemental heat is predictive of CO poisoning in patients who present to the ED with headache and dizziness.100
++
Absence of fuel-burning devices is not necessarily protective for CO poisoning. In multifamily homes, CO can diffuse through drywall, which is actually quite porous.89 During ice storms, blizzards, hurricanes, and other natural disasters with power loss, the indoor use of gasoline-powered generators115,218 and charcoal-burning grills, the latter particularly in immigrant populations, leads to epidemic CO poisoning outbreaks.23,25,234
++
Fires are another important source of CO exposure, contributing substantially to the approximate 5,613 smoke inhalation deaths each year.45 Carbon monoxide is considered to be the most common hazard to smoke inhalation victims.72,186 These cases are further compounded by the high incidence of hydrogen cyanide poisoning (Chap. 123).84
++
Carbon monoxide is readily absorbed after inhalation. The Coburn-Forster-Kane (CFK) model allows approximate prediction of carboxyhemoglobin (COHb) levels based on exposure history.46,48 A simplification of the model allows for estimation of the equilibrium based on the ambient concentration of CO in ppm: COHb (%) = 100/{1 + (643/ppm CO)}.214 This assumes that the individual weighs 70 kg and is not anemic. With exponential uptake, it takes more than 4 hours for equilibrium to be attained. Therefore, within minutes of high CO exposures, the arterial COHb level actually overshoots predicted estimates before equilibration.9,15 Endogenous production of CO is not factored in because its contribution to COHb is only 2%.
++
After its absorption, CO is carried in the blood, primarily bound to hemoglobin. The Haldane ratio states that hemoglobin has approximately a 200 to 250 times greater affinity for CO than for oxygen. Therefore, CO is primarily confined to the blood compartment, but eventually up to 15% of total CO body content is taken up by tissue, primarily bound to myoglobin.46 Therefore, the dissolved CO concentration in the plasma better reflects the ultimate potential for poisoning because it is available for diffusion into all tissue compartments, including the muscle and brain.135
++
Elimination of CO, like absorption, from the blood is modeled mathematically using the CFK model. The equation predicts a half-life of 252 minutes. In actual volunteer studies, means of 249 and 320 minutes breathing room air are reported.171 With 100% oxygen, these half-lives can be reduced significantly to means ranging 47 to 80 minutes in studies of volunteers who attain COHb levels of 10% to 12%.171,195 Patients poisoned with CO showed actual mean half-lives ranging from 74 to 131 minutes when treated with 100% oxygen.226,227
++
Methylene chloride, a paint stripper, is another source of CO. It is readily absorbed through the skin or by ingestion or inhalation and is metabolized in the liver to CO.191 Carboxyhyemoglobin levels peak 8 hours or later and range from 10% to 50%.134,177 Because of ongoing production of CO, the apparent COHb half-life is prolonged to 13 hours in these patients.176 Carboxyhyemoglobin levels after methylene chloride exposure are proportional to the concentration and duration of exposure.176
++
The most obvious deleterious effect of CO is binding to hemoglobin, rendering it incapable of delivering oxygen to the cells. Therefore, despite adequate partial pressures of oxygen in blood (PO2), there is decreased arterial oxygen content. Further insult occurs because CO causes a leftward shift of the oxyhemoglobin dissociation curve, thus decreasing the offloading of oxygen from hemoglobin to tissue (Fig. 28–2).180 This results in part from a decrease in erythrocyte 2,3-bisphosphoglycerate (2,3-BPG) concentration. The net effect of all these processes is the decreased ability of oxygen to be delivered to tissue.
++
Carbon monoxide toxicity cannot be attributed solely to COHb-mediated hypoxia. Neither clinical effects nor the phenomena of delayed neurologic deficits is completely predicted by the extent of binding between hemoglobin and CO.90,209 Furthermore, such a model fails to explain why even minimal levels of COHb (4%–5%) occasionally result in cognitive impairment. An early study showed that dogs breathing 13% CO died within 1 hour and had COHb levels of 54% to 90%. However, exchange transfusion of this same blood into healthy dogs to reach similar COHb levels caused no untoward effects.73 Hemorrhaging the dogs to comparable degrees of anemia also produced no adverse effects. The appropriate conclusion was that inherent to CO toxicity is its delivery to target organs such as the brain and heart and that although COHb is easily measured, it rarely has a significant contribution to clinical toxicity. For CO to reach tissue, it has to be dissolved in the plasma rather than bound to hemoglobin.79,80
++
Carbon monoxide interferes with cellular respiration by binding to mitochondrial cytochrome oxidase. Initial studies show that this binding is especially exaggerated under conditions of hypoxia and hypotension. In vitro rat models demonstrate that this oxidative stress causes mitochondrial damage with protein oxidation and lipid peroxidation, particularly in the hippocampus and corpus striatum.196 In vivo models reveal that CO poisoning causes cell loss in the frontal cortex, which is associated with decrements in learning and memory.172 Although no comparable brain studies exist in humans, the peripheral lymphocytes and monocytes of CO-poisoned patients show cytochrome oxidase inhibition accompanied by increased lipid peroxidation.71,146 In a small clinical series of CO-poisoned patients, normalization of this cytochrome activity lagged behind and seemed to agree better with symptom severity than COHb levels.147
++
Inactivation of cytochrome oxidase is only an initial part of the cascade of inflammatory events that results in ischemic reperfusion injury to the brain after CO poisoning (Fig. A40–1). During recovery from the initial poisoning, white blood cells are attracted to and adhere to the damaged brain microvasculature.201-203 This attraction is partly attributable to endothelial changes from initial cytochrome oxidase dysfunction, mediated primarily through the free radical nitric oxide (NO).201,207 Carbon monoxide displaces NO from platelets that in turn form peroxynitrites, which are even stronger inactivators of cytochrome oxidase.207 Multiple animal studies demonstrate that NO is ultimately responsible for much of the endothelial damage from CO and that NO synthase inhibitors can prevent toxicity.205,207 The NO formation promotes platelet–neutrophil aggregates that in turn lead to neutrophil adhesion to the brain microvasculature.202 Myelin peroxidase activation in the area further promotes neutrophil adhesion with degranulation and release of proteases that convert xanthine dehydrogenase to xanthine oxidase, an enzyme that promotes formation of oxygen free radicals.200 Also, mouse studies suggest that circulating microparticles play a proinflammatory role in activation of neutrophils.237 The end result of this process is delayed lipid peroxidation of the neurons, and the extent of destruction correlates with decrements in learning in rodents.200 Rats depleted of xanthine oxidase through a tungsten modified diet show no changes in myelin basic protein and cognitive function after CO poisoning.98
++
Simultaneously, with all this perivascular oxidative stress in the brain, there is activation of excitatory amino acids, which ultimately is responsible for the subsequent neuronal cell loss.207 In fact, in rat brains, glutamate concentrations increase after CO poisoning. Glutamate is an excitatory amino acid that binds at N-methyl-D-aspartate (NMDA) receptors and causes intracellular calcium release, resulting in delayed neuronal cell death (Chap. 13). Blockade of NMDA receptors prevents the neuronal death and learning deficits that accompany serious CO poisoning in mice.113 Increases in the glutamate concentrations in rat brain in the first hour after severe CO poisoning are followed by a later increase in hydroxyl radicals.172 Ultimately, at 1 to 3 weeks, the animals show histologic evidence of both neuronal necrosis and apoptosis in the frontal cortex, globus pallidus, and cerebellum that are accompanied by deficits in learning and memory.
++
Carbon monoxide neuronal cell death is partly attributable to apoptosis. In bovine pulmonary artery cells, CO exposure is accompanied by activation of caspase-1, a protease implicated in delayed cell death.206 Confirmatory evidence was provided in the same study because both caspase-1 and NO synthase inhibitors blocked apoptosis. The end result of all these cellular processes is brain injury, particularly in the basal ganglia and hippocampus.221 In some studies, this is accompanied by learning impairment.202 Thus, animal models correlate well with what ultimately occurs in victims of serious CO poisoning, namely, persistent or delayed deficits in learning and memory associated with structural changes in the brain.
++
Myoglobin, another heme protein, binds CO with an affinity about 60 times greater than it binds oxygen.49 About 10% to 15% of the total body store of CO is extravascular, primarily binding to myoglobin.15,46 A dog model demonstrates that this binding is enhanced under hypoxic conditions.49 This binding partially explains the myocardial impairment that occurs in both animal studies and low concentration exposures in patients with ischemic heart disease. The combination of COHb formation, which decreases oxygen-carrying capacity, and reduced myoglobin in the heart, which decreases oxygen extraction, contributes to the preterminal dysrhythmias that occurs in poisoned animals.
++
Several studies suggest that CO effects on the cardiovascular system are necessary for ischemic reperfusion injury of the brain. Hypotension is an essential component and results from a combination of myocardial depression and vasodilation. Carbon monoxide, perhaps because of its similarity to NO, activates guanylate cyclase, which in turn relaxes vascular smooth muscle. Also, CO further displaces NO from platelets, resulting in additional vasodilation.205 These factors contribute to the hypotension that occurs in animal experiments with exposure to high concentrations of CO.73 Such an episode of hypotension leads to syncope, portending a worse clinical outcome.40 In rhesus monkeys, cerebral white matter lesions correlate better with decreases in blood pressure than with COHb level.78 Lipid peroxidation of the brain in rats develops 1 hour after a CO exposure that has produced syncope and hypotension.199 This delay is comparable to the time that is necessary to produce mitochondrial destruction from oxidative stress in rats exposed to CO. In a feline model, central nervous system (CNS) damage from CO is reproduced only when hypoxia is accompanied by an interval of ischemia, confirming the ischemia reperfusion model.159
++
Endogenous CO behaves like NO, binding to guanylate cyclase and thereby increasing cyclic guanosine monophosphate (cGMP) concentrations.114 Although low endogenous concentrations are physiologic, excessive concentrations of CO from exogenous sources are problematic because CO persists much longer than NO. Carbon monoxide appears to be a neuronal messenger by virtue of the fact that as a gas, it can diffuse and signal adjacent cells.141
+++
CLINICAL MANIFESTATIONS
++
The earliest symptoms associated with CO poisoning are often nonspecific and readily confused with other illnesses, typically a viral syndrome223 (Table 122–2). The initial symptom reported by volunteers within 4 hours of exposure to 200 ppm CO (producing COHb levels of 15%–20%) is headache; shorter exposures at 500 ppm also produce nausea.192 The incidence of CO poisoning in symptomatic patients presenting to EDs in the winter with an influenzalike illness ranges from 3% to 24% in some series.61,101 The typical presenting complaints include headache, dizziness, and nausea, and the most frequent exposures occur during the winter, explaining why influenza is the most common misdiagnosis.61 The most common symptom, headache, is usually described as dull, frontal, and continuous. Carbon monoxide poisoning is also frequently misdiagnosed as food poisoning, gastroenteritis, and even colic in infants. Similar to adults, children tend to develop nonspecific symptoms, complicating diagnosis.
++
++
Continued exposure to CO leads to symptoms attributable to oxygen deficiency in the heart. Low-concentration exposures, leading to COHb levels of 2% to 4%, in volunteers with stable angina result in decreased exercise tolerance as well as signs and symptoms of myocardial ischemia.2 At higher levels (COHb of 6%), there is a greater frequency of premature ventricular contractions during exercise. Myocardial infarction and dysrhythmias are described in victims of CO poisoning, and acute mortality from CO is usually a result of ventricular dysrhythmias.2,3 Prolonged exposure to CO or high COHb levels are associated with temporary myocardial stunning, manifested as global hypokinesia or Takotsubo cardiomyopathy lasting usually less than 24.116,118 In some cases stunning, with decreased left ventricular ejection fraction, can last several days and is associated with increased concentrations of β-type natriuretic peptide, lactate, and troponin.132 Troponin elevations often occur even in the absence of any coronary artery disease or even electrocardiographic (ECG) or echocardiographic changes.31,55
++
These patients have an increased propensity for cardiac mortality, with almost one-third dying within 8 years after serious CO poisoning.102 A nationwide population based cohort study in Taiwan found an increased incidence of dysrhythmias, mostly paroxysmal tachycardia and ventricular fibrillation, in decade after CO poisoning of 8,381 subjects.131 Although serious CO exposures are associated with increased long-term mortality beyond 90 days, there was no association with increased cardiac death.87
++
The CNS is the organ system that is most sensitive to CO poisoning. Acutely, otherwise healthy patients may manifest headache, dizziness, and ataxia at COHb levels as low as 15% to 20%, with higher levels or longer exposures causing syncope, seizures, or coma.223 Focal neurologic findings suggest a cerebrovascular accident. Some cases have diffuse frontal slow-wave activity on electroencephalogram. Within 1 day of exposures that result in coma, many patients show decreased density in the central white matter and globus pallidus on computed tomography (CT) (Fig. 122–1) or magnetic resonance imaging (MRI).137 Autopsies show involvement of other areas, including the cerebral cortex, hippocampus, cerebellum, and substantia nigra.129
++
++
Metabolic changes reflect the toxic effects of CO better than any particular COHb level. Patients with mild CO poisoning develop respiratory alkalosis in an attempt to compensate for the reduction in oxygen-carrying capacity and delivery. More substantial exposures result in metabolic acidosis with lactate production that accompanies tissue hypoxia.189 Even in the absence of hypotension, lactate was an independent predictor of worse mental status and inpatient complications.30,60,150 The importance of metabolic acidosis was highlighted in a retrospective series of 48 CO-poisoned patients, in whom hydrogen ion concentration was a better predictor of poor recovery during initial hospitalization than was COHb level.216
++
Although the brain and heart are the most sensitive, other organs also manifest the effects of CO poisoning. One-fifth to one-third of patients with severe CO poisoning, particularly those requiring endotracheal intubation, develop pulmonary edema.82 This is caused by cardiac depression directly from CO or ARDS from associated smoke inhalation.118,186 This does not appear to be a direct effect of CO on lung tissue because sheep with prolonged exposure to CO, resulting in COHb levels greater than 50%, showed no anatomic or physiologic changes in lung function.185 Although myonecrosis and even compartment syndromes occur, patients rarely develop acute kidney injury (AKI). Retinal hemorrhages occur with exposures longer than 12 hours.120 Cherry-red skin coloration occurs only after excessive exposure (2%–3% of cases referred to one hyperbaric center) and represents a combination of CO-induced vasodilation, concomitant tissue ischemia, and failure to extract oxygen from arterial blood.178 Another classic but uncommon phenomenon is the development of cutaneous bullae after severe exposures. These bullae are thought to be caused by a combination of pressure necrosis and possibly direct CO effects in the epidermis.
+++
NEUROCOGNITIVE SEQUELAE
++
The persistent or delayed effects of CO poisoning are varied and include dementia, amnestic syndromes, psychosis, parkinsonism, paralysis, chorea, cortical blindness, apraxia and agnosia, peripheral neuropathy, and incontinence.133,233 If not diagnosed at initial poisoning, neurologic deterioration is delayed and preceded by a lucid period of 2 to 40 days after the initial poisoning.40 In patients admitted to an intensive care unit (ICU) for severe CO poisoning and treated with 100% oxygen, 14% of survivors had permanent neurologic impairment.123 In a Korean series of 2,360 CO-poisoned patients, 3% continued to show memory failure or parkinsonian features 1 year after exposure.40 Another series of 63 seriously poisoned patients showed memory impairment in 43% and deterioration of personality in 33% at 3-year follow-up.189 Children also develop behavioral and educational difficulties after severe poisoning.128 However, patients older than 30 years of age are more susceptible to the development of delayed sequelae.41,228 Most cases of delayed neurocognitive sequelae are associated with loss of consciousness (LOC) in the acute phase of toxicity.51
++
Neurocognitive sequelae probably involve lesions of the cerebral white matter.75 Weeks after exposure, autopsies show necrosis of the white matter, globus pallidus, cerebellum, and hippocampus. Magnetic resonance imaging studies confirm the damage to the white matter and hippocampus.70,137,223 Animal studies show that having a markedly elevated COHb level alone cannot cause similar white matter lesions but that there must also be an episode of hypotension.78,159 The fact that the areas permanently damaged in serious CO poisoning cases are the areas with the poorest vascular supply in the brain is consistent with these findings.
++
Often, patients complain of persistent headaches and cognitive problems after long-term exposure to low concentrations of CO. Unfortunately, to date, there have been no controlled studies demonstrating that in the absence of a severe acute poisoning episode, this type of exposure results in any long-term sequelae. Warehouse workers who are chronically exposed to CO from propane combustion have intermittent problems with headache, nausea, and lightheadedness.66 Fortunately, unless the individual had an episode of severe poisoning with acute deterioration, most workers achieve resolution of their symptoms.67 One series of patients with chronic CO poisoning demonstrates a high incidence of headache and memory complaints in addition to motor slowing and memory problems on neuropsychologic testing.153 Although many of the objective deficits improved with elimination of the exposure and HBO treatment, many continued to have posttraumatic stress and conversion disorders. Although it is uncertain whether chronic exposure to low concentrations of CO causes permanent damage, health care providers should be vigilant for symptomatic individuals to prevent continued or catastrophic outcomes.
++
The most useful diagnostic test obtainable in a suspected CO poisoning is a COHb level. Normal levels of COHb range from 0% to 5%. Levels at the high end of this range occur in neonates and patients with hemolytic anemia because CO is a natural byproduct of the breakdown of protoporphyrin to bilirubin.33 Of note, in blood samples from neonates, falsely high COHb levels up to 8% can occur because of interference of fetal hemoglobin with spectroscopy (Chap. 28).220 Carboxyhemoglobin levels average 6% in one-pack-per-day smokers but may range as high as 10%.190 Although high COHb levels confirm exposure to CO, particular levels are not necessarily predictive of symptoms or outcome.90,170
++
The usual method for measuring COHb is with a cooximeter, a device that spectrophotometrically reads the percentage of total hemoglobin saturated with CO. Traditionally, arterial blood was used for this determination; however, venous blood levels are accurate because there is little CO extraction from hemoglobin across the capillary bed.214 Refrigerated heparinized samples yield accurate COHb levels for months and at room temperature for 28 days, making retrospective clinical and postmortem evaluations reliable.86,125 The prior administration of hydroxocobalamin, commonly given for cyanide poisoning after smoke inhalation, negatively interferes with COHb levels on selected cooximeters, which could lead to false reassurance.136,164
++
Bedside tests using ammonia or sodium hydroxide are unable to differentiate reliably various levels of COHb versus control participants.161 Because of the similarities in extinction coefficients, COHb is misinterpreted as oxyhemoglobin on most types of pulse oximetry (Chap. 28).8 Thus, the pulse oximetry reading is usually normal in the setting of even severe CO poisoning.85 Some newer pulse oximeters, called pulse cooximeters, have the ability to measure COHb noninvasively.6 A study in 10 healthy volunteers who inhaled CO at 500 ppm until they reached a peak COHb level of 15% found good agreement between pulse cooximetry and cooximetry.7 Early models of a commercial bedside pulse cooximeter showed very poor agreement, mischaracterizing half the patients with levels over 15% as lower.214 Subsequently, two other cohorts of ED patients, using a later model of the same device, found that it measured COHb well, with a bias of 0.6% to 3% and precision of 3.3%.179,183 Because it tends to overestimate COHb, the authors recommend a normal upper limit of 6.6% as triggering intervention. Because the pulse cooximeter is noninvasive, it can be used for initial screening of ED patients for occult CO poisoning who present with nonspecific symptoms.37 Likewise, the device is useful for field screening, especially with mass casualties. But because of potential errors with its use, we agree with the American College of Emergency Physicians (ACEP) recent clinical guideline on CO poisoning that recommended it not be used independently to diagnose CO toxicity and therefore cannot substitute for a standard blood COHb measurement.232
++
Breath-sampling methods are used for screening patients.50,53,64 Cutoffs of 53 ppm in patients breathing air and 43 ppm in those breathing oxygen have a reliability of approximately 80% in predicting COHb levels above 10%.69 Limited data from French prehospital screening show no correlation between severity of CO poisoning and exhaled CO concentrrations.109 Therefore, because of its poor reliability, we do not recommend breath sampling for screening of hospitalized CO-poisoned patients.
++
Some clinical laboratories measure CO directly in blood samples rather than COHb. This technique involves assaying CO directly with infrared spectrophotometry after it is extracted from the blood sample with a manometer. Based on calculations rather than true experimental data, the assumption is made that for a patient with a normal hemoglobin, a CO level of 1 mmol/L corresponds to an 11% COHb concentration. A simpler method to measure serum CO content is to add a known solution of hemoglobin followed by sodium dithionite to form COHb. The resulting COHb is measured spectrophotometrically with the assumption that 1 mole of hemoglobin binds 4 moles of CO. Interestingly, in one study, serum CO ranged from 0.14 to 0.6 mg/L but was the same in smokers (average, 4.6% COHb) and nonsmokers (average, 1% COHb).230 At this time, further research is required to determine the clinical importance of serum CO content.
++
Additional laboratory tests are useful in severe poisoning cases. Metabolic acidosis with elevated lactate concentration is a more reliable index of severity than a measurement of the COHb concentration.189 Unfortunately, even arterial pH does not correlate well with either initial neurologic examination or the COHb level, making it a poor criterion for deciding the need for HBO treatment.152 Specificity of lactate is low in smoke inhalation victims, in whom it is used to indicate concomitant cyanide poisoning (Chap. 123).
++
Continuous cardiac monitoring and a 12-lead ECG are essential to identify ischemia or dysrhythmias in symptomatic patients with preexisting coronary artery disease or severe exposure. Mild elevations of creatine phosphokinase are common (ranging 20–1,315 IU/L in one series of 65 cases), usually because of rhabdomyolysis rather than cardiac sources.184 However, because CO causes myocardial infarction in the presence of normal coronaries,118 nonspecific increases in troponin concentrations may reflect diffuse cardiac myonecrosis rather than focal coronary artery disease.34 Congestive heart failure or hypotension can be evaluated with a β-type natriuretic peptide or echocardiography (or both), looking for evidence of myocardial stunning.33,118 Because of the potential for increased cardiovascular mortality,102 patients with ECG changes or elevated cardiac markers benefit from further cardiac testing, a stress test, or angiography.
++
The problem with using COHb levels to base treatment is that there is a wide variation in clinical manifestations across patients with identical COHb levels. Furthermore, particular COHb levels are not predictive of symptoms or final outcome.142,157,189 In a large prospective study of CO poisoning, COHb levels did not correlate with LOC and were not predictive of delayed neurologic sequelae.174 Admission COHb levels are inaccurate predictors of peak levels, and the use of nomograms to extrapolate to earlier levels is not validated. Their credibility is also suspect because of the great variability in COHb half-lives and differences in treatment with oxygen. To avert this problem, France equips prehospital personnel with cooximeters (model not stated), which, although imprecise do help them distinguish the severity of poisoining.109
++
Because of the inherent unreliability of COHb levels in predicting outcome, researchers are searching for other surrogate markers. Rats have early increases in glutathione released from erythrocytes, a potential marker for CO oxidative stress that could ultimately lead to brain injury.208 Another promising marker is serum S100B, a structural protein in astroglia that is released from the brain after hypoxic stress. A series of 38 consecutive patients poisoned with CO showed that those who presented with normal neurologic findings and no LOC had normal S100B concentrations.17 Patients who presented with LOC and neurologic deficits all had elevated concentrations. Carbon monoxide poisoned rats treated with HBO did not develop elevated S100B concentrations unlike those treated with ambient oxygen therapy.16 Levels at the target organ, the brain, show that S100B in the cerebrospinal fluid (CSF) predicted extreme neurologic sequelae, that is, persistent vegetative state only.110 Enolase, a byproduct of neuronal destruction, has a longer half-life than S100B and independently predicts delayed neurologic sequelae.32 Although markers used for cerebral injury, specifically S100B and neuron-specific enolase, rise after CO poisoning, they have not be shown to be reliable enough to predict final outcome or need for treatment.1,19,175 A recent pilot study concluded that almost 100 different plasma proteins—cytokines, chemokines, and other biomarkers—increase after CO poisoning in patients; their significance awaits more definitive studies.204
+++
NEUROPSYCHOLOGIC TESTING
++
The extent of neurologic insult from CO can be assessed with a variety of tests. The most basic is documentation of the normal neurologic examination, including a quick mini mental status examination. A more sensitive indicator of the acute effects of CO on cortical function is a detailed neuropsychologic test battery developed specifically for CO patients.145 The advantages of such testing, which usually takes about 30 minutes, are that it can reliably distinguish 79% of the time between CO-poisoned patients and control participants, and it shows improvement with appropriate HBO treatment.145 Unfortunately, such testing shows a sensitivity of only 77% and a specificity of 80% for CO poisoning. The patient can show practice effects as well with repeated testing. Another study suggested that the degree of impairment CO patients had on a test of short-term rote and context-aided verbal memory correlated well with the number of HBO treatments needed.144 The biggest problem with such neuropsychiatric testing is that it is uncertain whether the determined deficits found during the acute CO poisoning phase are at all predictive of the development of neurologic sequelae and therefore the necessity of HBO treatment.
++
Acute changes on CT scans of the brain occur within 12 hours of CO exposure that resulted in LOC.137,148 Symmetric low-density areas in the region of the globus pallidus, putamen, and caudate nuclei are frequently noted.105 Changes in the globus pallidus and subcortical white matter early within the first day after poisoning are associated with poor outcomes167 (Fig. 122–1). Alternatively, in one series of 18 patients, a negative CT within 1 week of admission was associated with favorable outcome.213 The use of contrast enhances the early isodense changes not visible on initial CT scan240 but is not routinely performed.
++
Magnetic resonance imaging is superior to CT in detecting cerebral white matter basal ganglia lesions after CO poisoning.137 One study found a much higher incidence of periventricular white matter changes on MRIs done within the first day after exposure. However, such changes had no correlation with COHb level or cognitive sequelae.167 These periventricular changes are more common and probably more sensitive than globus pallidus lesions. Globus pallidus lesions were present on MRI in only one patient (1.4%) in a prospective study of CO-poisoned patients, half of whom had LOC.105 Diffusion-weighted, or even diffusion tensor imaging MRI, has more promise in detecting changes in subcortical white matter within hours of serious CO poisoning.10,197 Regardless, neuroimaging usually does not influence patient management and can be reserved for patients who show poor response or have an equivocal diagnosis.
++
The most promising area of neuroimaging after CO poisoning is the assessment of regional cerebral perfusion.43,163 Single-photon emission CT (SPECT) gauges regional blood flow noninvasively using an iodine or technetium tracer. In one series of 13 patients with delayed neurologic sequelae (DNS), all cases showed patchy hypoperfusion throughout the cerebral cortex within 11 days of poisoning.41 These changes in perfusion occur as early as 1 day after poisoning and primarily involve watershed regions such as the temporoparietooccipital area.58 Perfusion defects on SPECT scanning are associated with neuropsychological impairment months after serious CO poisoning.70 In a recent series of CO-poisoned patients who required HBO, patients with DNS, rather than persistent neurologic sequelae, were more likely to show frontal hypoperfusion on SPECT scanning.107,215 Unfortunately, because of the scant availability of the procedure and the lack of comprehensive studies, SPECT scanning is not the definitive tool at this time for determining prognosis or need for HBO. In addition, when imaging patients 1 to 2 years after poisoning, T2-weighted imaging on MRI is more sensitive than SPECT scanning.38
++
Positron emission tomography (PET) can also be used to evaluate regional blood flow as well as oxygen metabolism in the brain after CO exposure. In one series of severely CO-poisoned patients, PET examination after HBO treatment showed increased oxygen extraction and decreased blood flow in the frontal and temporal cortices.56 Of note, patients with permanent deficits persisted in showing these abnormalities on PET scanning. One delayed PET study demonstrated that increases in dopamine D2 receptor binding in the caudate and putamen after CO poisoning were improved with bromocriptine, at which time neuropsychiatric symptoms resolved.239 Although PET scanning cannot be used to predict outcome, abnormalities that persist on the scan are associated with permanent neurologic sequelae. The same is true for proton magnetic resonance spectroscopy in which abnormalities within 1 week of exposure can predict DNS.126
++
Electroencephalograms (EEGs) complement perfusion studies in the evaluation of CO-poisoned patients. Although initial studies demonstrate that many patients have regional EEG abnormalities after poisoning, it is unknown if these are predictive of persistent or delayed neurologic problems. Electroencephalograms mapping may be discrepant relative to SPECT scanning because EEG preferentially demonstrates subcortical lesions.
++
The mainstay of treatment is initial attention to the airway. One hundred percent oxygen should be provided as soon as possible by either nonrebreather face mask or endotracheal tube. Although concerns have been raised regarding toxicity from excess oxygen, patients poisoned with CO can still have cellular hypoxia despite normal oxygen saturation.14,85 It is important to remember that a nonrebreathing mask only delivers 70% to 90% oxygen; a positive-pressure mask or an endotracheal tube is necessary to achieve higher oxygen concentrations. The immediate effect of oxygen is to enhance the dissociation of COHb.180 In volunteers, the half-life of COHb is reduced from a mean of 5 hours (range, 2–7 hours) when breathing room air (21% oxygen) to approximately 1 hour (range, 36–137 minutes) when breathing 100% oxygen at normal atmospheric pressure.171 Actual poisoned patients show a range in half-lives of 36 to 137 minutes (mean, 85 minutes) when breathing 100% oxygen; the longer elimination half-lives appear to be most often associated with long, low-level exposures.155,227 With oxygenation and intensive care treatment, hospital mortality rates for serious exposures range from 1% to 30%. The duration of treatment is unclear, with a valid end point being the resolution of symptoms, usually accompanied by a COHb below 5%.
++
Continuous cardiac monitoring and intravenous (IV) access are necessary in any patient with systemic toxicity from CO poisoning. Hypotension should initially be treated with IV fluids, with the addition of inotropes for persistent myocardial depression. An evaluation for cardiac ischemia, including ECG and cardiac markers, is recommended in symptomatic patients at risk: prolonged exposure (>2 hours), altered mental status, or male gender.31 Echocardiography is reasonable in such cases; almost three-quarters of CO-poisoned patients with elevated troponins showed cardiomyopathy with global dysfunction or Takotsubo like changes.33 Standard advanced cardiac life support protocols should be followed for the treatment of patients with life-threatening dysrhythmias. Patients with a depressed mental status should have a rapid blood glucose checked. Animal studies of CO poisoning suggest that hypoglycemia can be deleterious.168 We recommend not giving sodium bicarbonate for correction of any acidemia unless profound because it will cause left shift of the oxyhemoglobin dissociation curve, further impairing tissue oxygenation.62
++
Hyperbaric oxygen (HBO) therapy is still the treatment of choice for patients with significant CO exposures.210 But its most obvious effect is not the most important. One hundred percent oxygen at ambient pressure reduces the half-life of COHb from about 320 minutes to 85 minutes; at 2.5 atmospheres absolute (ATA), it is reduced to 20 minutes.171,227 Actual CO-poisoned victims treated with HBO have COHb half-lives ranging from 4 to 86 minutes.155 Hyperbaric oxygen also increases the amount of dissolved oxygen by about 10 times, which is sufficient alone to supply metabolic needs in the absence of hemoglobin (Chap. 28).12 This is rarely an important clinical issue because most patients are already stabilized and have appreciably decreased COHb with ambient oxygen before preparation for an HBO treatment.
++
Therefore, HBO is more than just a modality to clear COHb more quickly than ambient oxygen (Antidotes in Depth: A40). More importantly, in rats after LOC from CO exposure, hyperbaric, but not normobaric, oxygen therapy prevents brain lipid peroxidation.166 Hyperbaric oxygen therapy prevents ischemic reperfusion injury by a variety of mechanisms. First, in animal models, HBO accelerates regeneration of inactivated cytochrome oxidase, which is the initiating site for CO neuronal damage.12 Unlike 100% oxygen at room pressure, in clinical trials, HBO was much more effective than room pressure oxygen at restoring mitochondrial function within peripheral white blood cells in CO-poisoned patients.59 Hyperbaric oxygen also prevents β-integrin–mediated neutrophil adhesion to brain microvascular endothelium, a process essential for amplification of CNS damage from CO.178 In vitro studies of rat astrocytes show protective effects of HBO versus 100% oxygen in preventing impairment of neurotrophic activity after CO poisoning.117 All these animal studies explain why HBO, but not 100% oxygen at atmospheric pressure, prevents delayed deficits in a learning and memory maze model.202
++
Clinical studies of the effectiveness of HBO in preventing neurologic damage from CO are not as convincing as basic science studies would suggest. In uncontrolled human clinical series, the incidence of persistent neuropsychiatric symptoms, including memory impairment, ranged from 12% to 43% in patients treated with 100% oxygen and was as low as 0% to 4% in patients treated with HBO.82,143,154,157
++
Additionally, several controlled clinical trials have evaluated the efficacy of HBO in CO poisoning (Table 122–3). The first randomized study of CO poisoning included more than 300 patients and failed to show a benefit from HBO in patients who had no initial LOC.174 Unfortunately, seriously ill patients were not randomized to surface pressure oxygen; they received either one or three treatments of HBO. Flaws in the study included significant delays to treatment and the use of suboptimal pressure, 2.0 ATA, well below the greater than 2.5 ATA typically used in positive animal and human studies. A smaller (n = 60) controlled study avoided some of these flaws and showed that HBO, at a maximum pressure of 2.8 ATA, decreased delayed neurologic sequelae at 3 to 4 weeks from 23% to 0% in CO-poisoned patients who presented without LOC.211 However, patients with syncope, a marker of serious poisoning, were excluded. A very small study (n = 26) of patients presenting with Glasgow Coma Scale (GCS) scores above 12 after CO poisoning included almost half with LOC.63 Randomization to HBO versus 100% normobaric oxygen resulted in decreased EEG abnormalities and less reduction in blood flow reactivity to acetazolamide at 3 weeks. Unfortunately, all of these studies failed to definitively study all CO-poisoned patients, including those with syncope or coma.
++
++
The first randomized trial to directly address the issue of HBO efficacy in seriously CO-poisoned patients evaluated 191 CO-poisoned patients referred for HBO treatment.182 Patients were randomized to a minimum of three daily treatments of HBO (2.8 ATA for 60 minutes) or 100% oxygen at 1.0 ATA for 3 days. Although the HBO group had a higher incidence of persistent neurologic sequelae at 1 month, there was no significant difference between the two groups; more than two-thirds of each group had persistent problems. This study, although the largest controlled, randomized study to date, suffered from several flaws. Fewer than half of the patients had follow-up at 1 month. Disproportionate numbers of suicide cases (about two-thirds) and drug toxicity (44%), with accompanying neuropsychologic defects, likely confounded finding any beneficial effect from HBO. Finally, HBO treatment was delayed for 6 hours, making it much less likely to be effective.82,174
++
The landmark randomized, double-blind, placebo-controlled study of 152 CO-poisoned patients identified a beneficial effect of HBO.226 Most of these patients were ill, with a mean initial COHb level of 25% and a 50% incidence of LOC. Patients were all treated within 24 hours of exposure, but the success of the study might be partially attributable to the rapid mean time to treatment of less than 2 hours. Patients received HBO three times at intervals of 6 to 12 hours, each at 2.0 ATA, except for the first hour of the first treatment, which was at 3.0 ATA. Control patients received sham treatments in the HBO chamber with 100% oxygen at 1.0 ATA. At 6 weeks, the HBO group had a 24% incidence of cognitive sequelae versus 46% in the control group. Based on these data, the number of patients needed to treat to prevent one case of cognitive impairment is only five. Critics of this study point out that the neuropsychiatric tests were not significantly different between the groups except for digit spam and trail making, and there was no difference in activities of daily living. However, untreated patients had increased self-reported memory problems at 6 weeks (51% vs 28%), and the beneficial effect on cognitive sequelae persisted until 12 months.
++
A more recent study of 179 patients with transient LOC after CO poisoning showed no benefit from a single HBO treatment.5 Neurologic recovery at 1 month was approximately 60% regardless of HBO or normobaric oxygen. However, the study was done only at 2.0 ATA, and more than 20% of patients were lost to follow-up. The main effect of HBO is to prevent β2 integrins mediated adherence of neutrophils in the brain; this does not occur in animal studies until at least a pressure of 2.8 ATA is attained.210
++
Based on the strong animal and basic science experience, the positive human studies mentioned earlier, and few adverse effects, it is not surprising that the Underwater and Hyperbaric Medical Society (UHMS) recommends HBO for all CO patients with signs of serious toxicity.224 With the low risk of this procedure,181,188 almost 1,500 patients are treated with HBO for CO poisoning in the United States each year.93 Therefore, we believe that HBO is safe and indicated for serious CO poisoning, even though there is still substantial disagreement in the interpretation of the existing evidence regarding its usefulness.100,138,232
+++
Indications for Hyperbaric Oxygen Therapy
++
Although the specific recommendations for HBO after acute CO poisoning are listed (Table 122–4), they are not prospectively evaluated. The patients most likely to benefit are those most at risk for persistent or delayed neurologic sequelae, such as those presenting in coma or with a history of syncope.121 These are likely clinical markers for the episode of hypotension that are necessary for causing neuronal damage from CO-induced ischemic reperfusion injury in animal models.78,160 However, syncope is neither a particularly sensitive nor a specific marker for cognitive sequelae. Patients with long exposures, or “soaking” periods, typically longer than 6 hours, are also at greater risk for neurologic sequelae.13 The presence of a significant metabolic acidosis is a surrogate marker for CO poisoning.189,216 Patients who present with decreased level of consciousness, a GCS score of less than 9 in one series, had an odds ratio of 7.0 for the development of neurologic sequelae.170 Although some authors advocate ongoing myocardial ischemia as an indication for HBO, in our experience, these patients usually already meet neurologic criteria for treatment, such as LOC or ongoing mental status changes. Isolated cardiac ischemia, more importantly, deserves immediate proven myocardial salvaging therapy rather than delayed treatment with HBO.
++
++
Some authors advocate treating all patients with COHb levels of 40% or greater with HBO. It is reasonable to use a more conservative level of 25% as an indication for HBO.94 More important than actual level are patient history and examination. Further analysis of data from the most recent controlled trial demonstrates that in patients not treated with HBO, there were no reliable factors (COHb level, LOC, or base excess) for predicting who progressed to cognitive sequelae.229 A multivariate analysis showed that of all factors (LOC, age, exposure time, and COHb levels), only age of 36 years or older and CO exposure duration of 24 hours or longer were associated with cognitive dysfunction at 6-week follow-up. More problematic is the incidence of cognitive sequelae in patients without those risk factors: 32% in those younger than age 36 years and 36% in those with less than 24 hours of exposure. In conclusion, it appears that there are no completely reliable predictors for screening out patients who will do well without HBO treatment.
++
Multiple studies attempted to evaluate serum markers after acute CO poisoning that would predict neurologic sequelae. Although COHb confirms exposure, it does not correlate with future outcome, let alone acute symptoms.90,228 Multiple serum markers, including cytokines, increase after CO poisoning, but their predictive accuracy is unclear.204 Although impaired mitochondrial cytochrome function and elevated lipid peroxidation are seen in peripheral lymphocytes and monocytes after clinical CO poisoning, they only confirm CO exposure and are too nonspecific to use as predictors of neurologic sequelae.71
++
Therefore, at this time, it is prudent to refer for HBO treatment those patients with the most serious neurologic symptoms, regardless of their COHb level. Such symptoms include coma, seizures, focal neurologic deficits, altered mental status (GCS score <15), and although controversial, LOC. Patients who have had cardiac arrest from CO poisoning and had the return of spontaneous circulation are poor candidates for HBO therapy because virtually all these cases are fatal.97 In fact, such deaths from CO poisoning are not contraindication to organ donation (Special Considerations: SC12).
++
Excluding patients from HBO with milder symptoms after CO poisoning is problematic because even they are susceptible to neurocognitive sequelae. One series of 55 patients with mild poisoning as defined by the absence of LOC and maximum measured COHb level less than 15% found that even one-third of these individuals had neurocognitive sequelae up to 12 months after exposure.35 This was no different than that occurring in the severely poisoned group, although the milder group had a much longer duration of exposure as well as a greater delay to the evaluation of the COHb level. Brain imaging studies confirm that mild exposures, marked by no LOC and COHb levels lower than 15%, result in visible changes.70,173 Taken to its logical but impractical conclusion, because even apparently mild cases of CO poisoning have poor neurocognitive outcomes, HBO treatment of every CO-exposed patient, regardless of severity, could be justified.
++
It is still unclear if mild neurologic effects, such as confusion, headache, dizziness, visual blurring, or abnormal mental status testing on initial presentation after CO poisoning, are prognostic for cognitive sequelae, which would necessitate HBO treatment. These effects simply represent CO poisoning, which at COHb levels approaching 10% in volunteers causes temporary impairment of learning and memory.4 In one prospective clinical trial of CO poisoning, the incidence of cerebellar dysfunction portended a higher incidence of cognitive sequelae (odds ratio, 5.7; 95% confidence interval {CI}, 1.7–19.3).226 Therefore, difficulties with finger-to-nose, heel-to-shin, rapid alternating hand movements, or even ataxia are recommended indications for HBO. Patients with other mild neurologic findings, such as headache, warrant at least several hours of oxygen by nonrebreather facemask until symptoms resolve. If symptoms do not resolve, HBO is recommended; however, any delay to HBO therapy decreases its efficacy.
++
A more promising method to discern patients who may respond to HBO is based on the genotype, apolipoprotein E, specifically the isoform ε4.106 This particular polymorphism allele is present in up to one-quarter of the population, and it is associated with worse neurologic outcome from trauma and stroke. In the presence of CO poisoning, it is associated with lack of response to HBO for preventing neurocognitive sequelae. Further studies support not treating patients with this particular allele, focusing on those with the potential for response to HBO therapy.
++
Several professional societies have attempted to develop evidence-based guidelines. The American College of Emergency Physicians stated that no clinical variable predicts patients at risk of cognitive sequelae of likelihood to benefit from HBO.231 The American College of Emergency Physicians guideline recently stated that it remains unclear if HBO provides any added benefit over normobaric oxygen therapy in preventing long-term neurocognitive sequelae.232 Similarly, the Cochrane Collaboration review on the use of HBO in CO poisoning concluded that because of so much conflicting data, there is insufficient evidence to support HBO for CO poisoning at this time.18 The collective odds ratio for protective effect at 4 to 6 weeks with HBO versus normobaric oxygen was 0.78 (95% CI 0.54–1.12) based on a collective experience of 1,361 patients in six studies. The most recent guideline from the UHMS states that CO-poisoned patients should be referred for HBO if they have serious poisoning, such as unconsciousness, whether it is transient or persistent; age 36 years or older; or CO exposure duration of 24 hours or longer, even if intermittent.224 These guidelines are consistent with the prior studies discussed earlier. The UHMS guidelines also state that many physicians treat when neuropsychologic testing results are abnormal or COHb levels are greater than 25% to 30%.
++
Some authors recommend selective use of HBO because of cost and difficulties in transport if the primary facility lacks a chamber. However, complications that make such transfers and treatment unsafe are rare.188 At the present time, we routinely recommend HBO for selected patients poisoned by CO based on the indications in Table 122–4. Fortunately, even without HBO, anywhere from one-third to three-quarters of cases with persistent cognitive sequelae resolve over the subsequent year.40,226
+++
Delayed Administration of Hyperbaric Oxygen
++
The optimal timing and number of HBO treatments for CO poisoning is unclear. Patients treated later than 6 hours after exposure tend to have worse outcomes in terms of delayed sequelae (30% versus 19%) and mortality (30% versus 14%).82 This helps explain the failure of one of the first randomized trials on HBO for CO poisoning, which had a mean time to treatment of over 6 hours after poisoning.182 Meanwhile, HBO treatments delivered within 6 hours after poisoning in patients with LOC after CO seem to almost completely prevent neurologic sequelae.241 However, patients benefit even if treated later. In the most recent randomized clinical trial showing beneficial effects of HBO, although all patients were treated within 24 hours of exposure, 38% of patients were treated later than 6 hours after exposure. Therefore, it is reasonable to perform HBO, contingent on transport limitations, within 24 hours of presentation for symptomatic acute poisoning.
++
One case series suggests beneficial effects for HBO used up to 21 days after exposure, even after patients have developed neuropsychologic sequelae.154 The problem with studies showing HBO benefits days after an acute poisoning or after chronic poisoning is that these cases are all anecdotal and lack control participants. In fact, delayed neurocognitive sequelae frequently resolve within 2 months in patients with mild CO poisoning,211 and in those with serious CO poisoning who survive to HBO treatment, one-third resolve within 1 year.226 It is possible that these delayed or chronic cases simply represent the placebo effect of HBO.
+++
Repeat Treatment with Hyperbaric Oxygen
++
A randomized clinical trial demonstrated that three HBO treatments within the first 24 hours improved cognitive outcome.226 Unfortunately, there was no group treated with only one or two HBO sessions in that study. Regardless, it is reasonable to give repeated treatments for patients with persistent symptoms, particularly coma, who do not resolve after their first HBO session. In a pilot study, one HBO treatment was enough to promote almost total mitochondrial cytochrome activity, as measured in peripheral lymphocytes, after CO poisoning.71 In a nonrandomized retrospective study, CO-poisoned patients who received a second HBO treatment had a reduction in delayed neurologic sequelae from 55% to 18% compared with control participants who had only one treatment.81
++
It is not clear that more HBO treatments are better. A large recent study showed that in seriously poisoned CO patients, two hyperbaric treatments resulted in a worse outcome than one treatment, with complete recovery in 47% versus 68%, respectively.5 There were serious flaws in that study, including lack of formal neuropsychological testing and the use of only 2.0 ATA of pressure, well below the 3.0 ATA used initially in favorable studies. A recent retrospective nationwide study in Taiwan showed that patients treated for CO poisoning with more than one treatment had lower mortality rates (adjusted hazard ratio of 0.79; 95% CI 0.64–0.95) over the subsequent 4 years, than those receiving only one treatment.108 With the lack of prospective studies comparing single versus multiple courses of HBO therapy, multiple treatments are not recommended as a routine at this time. The most recent clinical guidelines from the UHMS state that the optimal number of HBO treatments for CO poisoning is unknown and that one should consider reserving multiple treatments for patients who fail to fully recover after one treatment.224
+++
Treatment of Pregnant Patients
++
The management of CO exposure in the pregnant patient is difficult because of the potential adverse effects of both CO and HBO. A literature review of all CO exposures during pregnancy revealed a high incidence of fetal CNS damage and stillbirth after severe maternal poisonings.217 A series of three severely symptomatic patients who did not receive HBO had adverse fetal outcomes: two stillbirths and one case of cerebral palsy.122 There are cases of limb malformations, cranial deformities, and a variety of mental disabilities in children poisoned in utero.20,139,140 A recent epidemiologic study in Guatemala showed that CO exposure from wood smoke during the third trimester was inversely associated with neuropsychological performance at ages 6 to 7 years when corrected for socioeconomic confounders.59
++
Traditionally, it was thought that fetal hemoglobin had a high affinity for CO. Pregnant ewe studies show a delayed but substantive increase in COHb levels in fetuses, exceeding the level and duration of those in the mothers.140 Thus, it appeared that fetuses were a sink for CO and could be poisoned at concentrations lower than mothers. However, such data do not apply to humans because in vitro work shows that as opposed to sheep, human fetal hemoglobin actually has less affinity for CO than maternal hemoglobin, at a ratio of 0.8. Under conditions of low oxygenation and high 2,3-BPG, as in serious CO poisoning, the affinity of human fetal hemoglobin starts to approach that of maternal.229 The more important issue with maternal CO exposure is the precipitous decrease in fetal arterial oxygen content that occurs within minutes at CO concentrations of 3,000 ppm.77 Therefore, the ensuing hypoxia of the fetus, rather than increase in fetal COHb, is of more concern.
++
Maternal COHb levels do not accurately reflect fetal hemoglobin or tissue concentrations.51 In primate studies, a single CO exposure insufficient to cause clinical disease in the mother led to intrauterine hypoxia, fetal brain injury, and an increased rate of fetal death.76,78 In humans, there are a few cases of fetal demise with maternal levels of COHb less than 10%.20 However, in that series, some mothers were treated with oxygen before their COHb levels were obtained. Another issue with some of these data is that often the mother was chronically “soaked” with CO, making levels difficult to interpret. Rodent studies show that chronic low-level CO exposure in pregnant mothers may result in permanent cognitive deficits in the subsequent progeny.57
++
Because maternal COHb does not necessarily predict fetal demise, clinicians must direct their attention to maternal manifestations of CO toxicity. Multiple case series demonstrate that pregnant women who present with a normal mental status and no LOC after CO poisoning have excellent outcomes in terms of normal deliveries.20,122 These infants have no subsequent delay in attaining their developmental milestones. Therefore, it appears that mothers who appear well after acute CO poisoning will have good outcomes with respect to their pregnancies.
++
The bigger dilemma for clinicians is the approach to treatment of seriously symptomatic CO-poisoned pregnant patients. All patients should receive 100% oxygen by face mask, at least until the mother is asymptomatic. However, CO absorption and elimination are slower in the fetal circulation than in the maternal circulation.140 A mathematical model predicts that elimination of CO from fetuses takes 3.5 times longer than maternal CO elimination.103 However, because some of these data are based on sheep fetal hemoglobin kinetics, the optimum time for treatment of the mother cannot be recommended at this time.
++
Unfortunately, pregnant patients were excluded from all prospective trials documenting the efficacy of HBO. However, treatment of pregnant patients with HBO is not without theoretical risk. Animal studies show conflicting results on the effects of HBO on fetal development. Some studies demonstrate that HBO causes developmental abnormalities in the central nervous, cardiovascular, and pulmonary systems of rodent fetuses. This is in marked contrast to the extensive Russian experience, in which hundreds of pregnant women were treated with HBO, apparently without significant perinatal complications and with improvement in fetal and maternal status for their underlying conditions of toxemia, anemia, and diabetes.149 There are multiple cases where apparently normal infants are born after their pregnant mothers received HBO for mild CO poisoning. However, less than optimal outcomes have occurred in cases of sicker patients in which the mother has had LOC or presented comatose.65 A 25-year longitudinal study of 406 pregnant women who received HBO for CO poisoning, with many children followed for up to 6 years of age, showed no psychomotor or growth differences between exposed and unexposed control participants.222 Thus, it appears that HBO should be safe and have the same efficacy for pregnant patients as in nonpregnant patients. There currently is no scientific validation for an absolute level at which to provide HBO therapy for a pregnant patient with CO exposure. Somewhat arbitrarily, we recommend a threshold for HBO in pregnant patients is a COHb level regardless of symptoms of greater then or equal to 15%. Pregnant patients should not be treated any differently if they meet criteria for HBO described above (Table 122–4). Additional criteria include any signs of fetal distress, such as abnormal fetal heart rate.
+++
Treatment of Children
++
It is suggested that children are more sensitive to the effects of CO because of their increased respiratory and metabolic rate.39 Epidemiologic studies suggest that children become symptomatic at COHb levels less that 10%, which is lower than commonly expected in adults.121 The other problem is that these younger patients have unusual presentations. Although most children manifest nausea, headache, or lethargy, an isolated seizure or vomiting is sometimes the only manifestation of CO toxicity in an infant or child.39
++
When interpreting COHb levels in infants, clinicians must be aware of two confounding factors. First, many older cooximeters give falsely elevated COHb levels in proportion to the amount of fetal hemoglobin present.219 Second, CO is produced during breakdown of protoporphyrin to bilirubin. Therefore, infants normally have higher levels of COHb, which are even higher in the presence of kernicterus. Some neonates not exposed to CO have COHb levels approaching 8%.220 Thus, before it is assumed that an elevated COHb level implies CO poisoning in an infant, the contribution of jaundice and fetal hemoglobin must be evaluated.
++
There are alternative clinical markers better than COHb for gauging toxicity in children. An elevated lactate concentration was found in 90.1% of 674 pediatric patients admitted for CO poisoing.54 Many children with elevated troponin concentrations after CO poisoning had normal ECGs or just subtle transitory T-wave changes from repolarization abnormalities.162 The echocardiogram is abnormal approximately 50% of patients found to have an elevated troponin concentration, usually showing a temporary decrease in left ventricular function and ejection fraction.162,198
++
Although children are more susceptible to acute toxicity with CO, their long-term outcomes appear to be more favorable than for adults. In one series of 2,360 serious CO cases, all cases of delayed neurologic sequelae occurred in adults older than age 30 years.40 Another series of CO poisoning demonstrated an incidence of delayed neurologic sequelae of 10% to 20% in children after severe CO poisoning.39 Increased COHb levels (>25%) in adolescents associated with more severe acute symptoms.127 One retrospective multivariate analysis showed that prolonged LOC requiring ICU care was the only independent risk factor for delayed neurologic sequelae.36
++
This low incidence of DNS in patients treated only with 100% oxygen at normal pressures is used as an argument to avoid HBO. However, their risk of such sequelae exists, and HBO is used successfully to prevent it.238 In a recent series of 27 hospitalized children for CO poisoning treated with HBO, only 1 child had minor neurologic sequelae (ie, headache and tinnitus).119 Deaths in children are often directly related to concomitant smoke inhalation.42 The CoHb half life with surface pressure oxygen is approximately 44 minutes, faster elimination than occurs in adults.121 Often, children exposed to CO under similar circumstances with a parent, although appearing well, are treated simultaneously with the sick parent, especially if a multiplace chamber is available.
+++
Novel Neuroprotective Treatments
++
A variety of neuroprotective therapeutics were tested in animal models. They are targeted primarily at preventing the delayed neurologic sequelae associated with serious CO poisoning. One of the simplest treatments tested is insulin. Hyperglycemia exacerbates neuronal injury from stroke as well as in arrest situations. In CO poisoning of rodents, it is associated with worse neurologic outcome.138 However, insulin, independent of its glucose-lowering effect, is protective after ischemic insults. In rodent studies, improved neurologic outcome, as measured by locomotor activity, occurs in those with CO poisoning treated with insulin. In light of these findings, it is reasonable to treat documented hyperglycemia with insulin in patients with serious CO poisoning.
++
Many neuroprotective therapeutics involve blockage of excitatory amino acids that are implicated in neuronal cell death after CO poisoning. Pretreatment of mice with dizocilpine (MK-801), which blocks the action of glutamate at N-methyl-D-aspartate receptors, ameliorates learning, memory, and hippocampal deficits with CO poisoning.113 Ketamine, another glutamate antagonist, decreases the mortality rate of rats poisoned with CO after carotid ligation.169 Treatment of mice with various glutamate antagonists prevents learning and memory deficits in a model of CO poisoning.74 Blockage earlier in the immunologic cascade, with a neuronal NO synthase inhibitor also prevented NMDA receptor activation, thus protecting mice from learning deficits after CO poisoning.207 Further clinical research is needed before recommending any of these antagonists routinely.
++
One exciting approach is the use of antioxidants, such as dimethyl sulfoxide and disulfiram, that prevent learning and memory deficits when given after CO poisoning in mice.74 Use of these or related therapeutics, although promising, awaits further animal testing because of potential adverse effects. Likewise, 3-N-butylphtalide, a celery seed extract, which has a variety of neuroprotective effects, including improved blood flow, antioxidant, and antiapoptosis effects, was adopted from stroke research. A randomized trial of 185 seriously CO-poisoned patients treated with HBO showed that by adding 3-N-butylphthalide 200 mg three times a day orally, neurologic remission improved.236 Regardless of treatment, both treated and untreated groups showed improvement.
++
Much of what happens after CO poisoning involves an inflammatory cascade that leads eventually to neurologic sequalae. A recent trial of patients receiving HBO for CO poisoning were randomized to treatment with 5 and 10 mg/day of dexamethasone versus HBO alone.235 Both dexamethasone groups showed improved scores on mini mental state examination as well as the National Institute of Health Stroke Scale at 4 weeks after poisoning. This was accompanied by a decrease in myelin basic protein in CSF, confirming the antiinflammatory effect of the drug. Erythropoietin is another potential treatment modality for CO poisoning that also decreases the neuronal inflammatory response.166 A human trial showed that the addition of recombinant erythropoietin daily for 1 week to HBO decreased the incidence of delayed neurologic sequelae from 30% in the HBO alone to 12%.165
++
Other modalities tested in preventing neuronal damage from CO are not successful. Although hypothermia was associated with good outcomes in uncontrolled human trials,68,158 controlled animal trials actually show an increased mortality rate.194 Allopurinol, which prevents the formation of free radicals through xanthine oxidase, inhibits lipid peroxidation in CO poisoning when given before exposure.202 This strategy is not promising because of the necessity for pretreatment.
++
Early diagnosis prevents much of the morbidity and mortality associated with CO poisoning, especially in unintentional exposures. The increased quality of home CO-detecting devices allows personal intervention in the prevention of exposure.124 If a patient presents complaining that his or her CO alarm sounded, it is important to realize that the threshold limit for the alarm is set roughly to approximate a COHb level of 10% at worst. Therefore, manufacturers must have their alarms activate within 189 minutes at 70 ppm CO, 50 minutes at 150 ppm, and 15 minutes at 400 ppm (Underwriters Laboratories, UL2034). Alarms are not designed to activate for prolonged exposures below 30 ppm to prevent epidemic alarming during winter thermal inversions in large cities.11 Government ordinances for obligatory CO alarms could potentially prevent many poisonings, particularly during winter storms.23,83 Although most serious CO poisonings are associated with the absence of CO alarms, a small proportion of such patients had alarms, suggesting the need for assessing proper functionality after installation.44
++
Routine laboratory screening of ED patients during the winter is not very efficacious in diagnosing unsuspected CO poisoning; the yield is less than 1% for patients tested in whom the diagnosis of CO exposure was already excluded by history. Instead, selecting patients with CO-related complaints, such as headache, dizziness, or nausea, increases the yield to 5% to 11%.64,193 During the winter, risk factors such as gas heating or symptomatic cohabitants in patients with influenzalike symptoms such as headache, dizziness, or nausea, particularly in the absence of fever, is the most useful method for deciding when to obtain COHb levels for potential patients.
++
The issue of symptomatic cohabitants is especially important from a preventive standpoint. Alerting other cohabitants to this danger and effecting evacuation prevents needless morbidity and mortality. This is especially critical for multifamily domiciles, such as hotels, that have resulted in dramatic collective exposures and even deaths.225 Most communities have multiple resources for onsite evaluation. Usually the local fire department or utility company can either check home appliances or measure ambient CO concentrations with portable monitoring equipment. The current workplace standard for ambient CO exposures is 35 ppm averaged over 8 hours with a ceiling limit of 200 ppm (measured over a 15-minute period).99 Just a 4-hour exposure to 100 ppm of CO may result in COHb level greater than 10% with symptoms.
++
Unintentional exposures to CO are easily missed or misdiagnosed. Patients with a suspected influenzalike illness should be screened for potential home sources of CO, and symptomatic cohabitants should be alerted.
Carbon monoxide exposure should be evaluated in patients with unexplained coma, metabolic acidosis, or signs of cardiac ischemia, especially if attempted suicide is suspected.
Fire victims, in addition to airway complications and potential cyanide and other toxic inhalants may succumb to CO toxicity.
The mainstay of treatment in CO poisoning is good supportive care with early oxygenation to increase the elimination of COHb.
Because of the overwhelming clinical successes with HBO and its limited risks, early use of this treatment modality in severe exposures is recommended.
Discussion with a regional poison control center or hyperbaric facility will help in identifying patients who are most likely to benefit from such treatment.
1. +
Akdemir
HU, et al. The role of S100B protein, neuron-specific enolase, and glial fibrillary acidic protein in the evaluation of hypoxic brain injury in acute carbon monoxide poisoning.
Hum Exp Toxicol. 2014;33:1113–1120.
[PubMed: 24505052]
2. +
Allred
EN, et al. Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease.
N Engl J Med. 1989;321:1426–1432.
[PubMed: 2682242]
3. +
Allred
EN, et al. Effects of carbon monoxide on myocardial ischemia.
Environ Health Perspect. 1991;91:89–132.
[PubMed: 2040254]
5. +
Annane
D, et al. Hyperbaric
oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials.
Intensive Care Med. 2011;37:486–492.
[PubMed: 21125215]
6. +
Barker
SJ, Badal
JJ. The measurement of dyshemoglobins and total hemoglobin by pulse oximetry.
Curr Opin Anaesthesiol. 2008;21:805–810.
[PubMed: 18997533]
7. +
Barker
SJ, et al. Measurement of carboxyhemoglobin and methemoglobin by pulse oximetry: a human volunteer study.
Anesthesiology. 2006;105:892–897.
[PubMed: 17065881]
8. +
Barker
SJ, Tremper
KK. The effect of carbon monoxide inhalation on pulse oximetry and transcutaneous PO2.
Anesthesiology. 1987;66:677–679.
[PubMed: 3578881]
9. +
Benignus
VA, et al. Prediction of carboxyhemoglobin formation due to transient exposure to carbon monoxide.
J Appl Physiol (1985). 1994;76:1739–1745.
[PubMed: 8045854]
10. +
Beppu
T. The role of MR imaging in assessment of brain damage from carbon monoxide poisoning: a review of the literature.
AJNR Am J Neuroradiol. 2014;35:625–631.
[PubMed: 23598831]
11. +
Bizovi
KE, et al. Night of the sirens: analysis of carbon monoxide-detector experience in suburban Chicago.
Ann Emerg Med. 1998;31:737–740.
[PubMed: 9624314]
12. +
Boerema
I, et al. [Life without blood].
Ned Tijdschr Geneeskd. 1960;104:949–954.
[PubMed: 13802034]
13. +
Bogusz
M, et al. A comparison of two types of acute carbon monoxide poisoning.
Arch Toxicol. 1975;33:141–149.
[PubMed: 1242299]
14. +
Brown
SD, Piantadosi
CA. Recovery of energy metabolism in rat brain after carbon monoxide hypoxia.
J Clin Invest. 1992;89:666–672.
[PubMed: 1737854]
15. +
Bruce
EN, Bruce
MC. A multicompartment model of carboxyhemoglobin and carboxymyoglobin responses to inhalation of carbon monoxide.
J Appl Physiol (1985). 2003;95:1235–1247.
[PubMed: 12754170]
16. +
Brvar
M, et al. S100B protein in conscious carbon monoxide-poisoned rats treated with normobaric or hyperbaric
oxygen.
Crit Care Med. 2006;34:2228–2230.
[PubMed: 16763504]
17. +
Brvar
M, et al. S100B protein in carbon monoxide poisoning: a pilot study.
Resuscitation. 2004;61:357–360.
[PubMed: 15172716]
18. +
Buckley
NA, et al. Hyperbaric
oxygen for carbon monoxide poisoning.
Cochrane Database Syst Rev. 2011:CD002041.
19. +
Cakir
Z, et al. S-100beta and neuron-specific enolase levels in carbon monoxide-related brain injury.
Am J Emerg Med. 2010;28:61–67.
[PubMed: 20006203]
20. +
Caravati
EM, et al. Fetal toxicity associated with maternal carbon monoxide poisoning.
Ann Emerg Med. 1988;17:714–717.
[PubMed: 3382073]
21. +
Centers for Disease Control and Prevention. Carbon monoxide poisoning at an indoor
ice arena and bingo hall—Seattle, 1996.
MMWR Morb Mortal Wkly Rep. 1996;45:265–267.
[PubMed: 8596526]
22. +
Centers for Disease Control and Prevention. Carbon-monoxide poisoning resulting from exposure to ski-boat exhaust—Georgia, June 2002.
MMWR Morb Mortal Wkly Rep. 2002;51:829–830.
[PubMed: 12353743]
23. +
Centers for Disease Control and Prevention. Epidemic carbon monoxide poisoning despite a CO alarm law. Mecklenburg County, NC, December 2002. MMWR Morb Mortal Wkly Rep. 2004;2004.
24. +
Centers for Disease Control and Prevention. Use of carbon monoxide alarms to prevent poisonings during a power outage—North Carolina, December 2002.
MMWR Morb Mortal Wkly Rep. 2004;53:189–192.
[PubMed: 15017373]
25. +
Centers for Disease Control and Prevention. Carbon monoxide poisoning from hurricane-associated use of portable generators—Florida, 2004.
MMWR Morb Mortal Wkly Rep. 2005;54:697–700.
[PubMed: 16034315]
26. +
Centers for Disease Control and Prevention. Unintentional non-fire-related carbon monoxide exposures—United States, 2001-2003.
MMWR Morb Mortal Wkly Rep. 2005;54:36–39.
[PubMed: 15660017]
27. +
Centers for Disease Control and Prevention. Carbon monoxide–related deaths—United States, 1999-2004.
MMWR Morb Mortal Wkly Rep. 2007;56:1309–1312.
[PubMed: 18097342]
28. +
Centers for Disease Control and Prevention. Nonfatal, unintentional, non–fire-related carbon monoxide exposures—United States, 2004-2006.
MMWR Morb Mortal Wkly Rep. 2008;57:896–899.
[PubMed: 18716581]
29. +
Centers for Disease Control and Prevention. QuickStats: number of deaths resulting from unintentional carbon monoxide poisoning, by month and year—National Vital Statistics System, United States, 2010-2015.
MMWR Morb Mortal Wkly Rep. 2017;66:234.
[PubMed: 28253228]
30. +
Cervellin
G, et al. Initial blood lactate correlates with carboxyhemoglobin and clinical severity in carbon monoxide poisoned patients.
Clin Biochem. 2014;47:298–301.
[PubMed: 25262985]
31. +
Cha
YS, et al. Features and predictors of myocardial injury in carbon monoxide poisoned patients.
Emerg Med J. 2014;31:210–215.
[PubMed: 23349356]
32. +
Cha
YS, et al. Serum neuron-specific enolase as an early predictor of delayed neuropsychiatric sequelae in patients with acute carbon monoxide poisoning. Hum Exp Toxicol. 2017:960327117698544.
33. +
Cha
YS, et al. Incidence and patterns of cardiomyopathy in carbon monoxide-poisoned patients with myocardial injury.
Clin Toxicol (Phila). 2016;54:481–487.
[PubMed: 27064298]
34. +
Chamberland
DL, et al. Transient cardiac dysfunction in acute carbon monoxide poisoning.
Am J Med. 2004;117:623–625.
[PubMed: 15465519]
35. +
Chambers
CA, et al. Cognitive and affective outcomes of more severe compared to less severe carbon monoxide poisoning.
Brain Inj. 2008;22:387–395.
[PubMed: 18415719]
36. +
Chang
YC, et al. Risk factors and outcome analysis in children with carbon monoxide poisoning.
Pediatr Neonatol. 2017;58:171–177.
[PubMed: 27502424]
37. +
Chee
KJ, et al. Finding needles in a haystack: a case series of carbon monoxide poisoning detected using new technology in the emergency department.
Clin Toxicol (Phila). 2008;46:461–469.
[PubMed: 18568803]
38. +
Chen
NC, et al. Detection of gray matter damage using brain MRI and SPECT in carbon monoxide intoxication: a comparison study with neuropsychological correlation.
Clin Nucl Med. 2013;38:e53–59.
[PubMed: 23334141]
39. +
Cho
CH, et al. Carbon monoxide poisoning in children.
Pediatr Neonatol. 2008;49:121–125.
[PubMed: 19054917]
41. +
Choi
IS, et al. Evaluation of outcome of delayed neurologic sequelae after carbon monoxide poisoning by technetium-99m hexamethylpropylene amine oxime brain single photon emission computed tomography. Euro Neurol. 1995;35:137–142.
42. +
Chou
KJ, et al. Characteristics and outcome of children with carbon monoxide poisoning with and without smoke exposure referred for hyperbaric
oxygen therapy.
Pediatr Emerg Care. 2000;16:151–155.
[PubMed: 10888449]
43. +
Chu
K, et al. Diffusion-weighted MRI and 99mTc-HMPAO SPECT in delayed relapsing type of carbon monoxide poisoning: evidence of delayed cytotoxic edema.
Eur Neurol. 2004;51:98–103.
[PubMed: 14752216]
44. +
Clower
JH, et al. Recipients of hyperbaric
oxygen treatment for carbon monoxide poisoning and exposure circumstances.
Am J Emerg Med. 2012;30:846–851.
[PubMed: 21855265]
46. +
Coburn
RF. The carbon monoxide body stores.
Ann N Y Acad Sci. 1970;174:11–22.
[PubMed: 4943970]
47. +
Coburn
RF. Endogenous carbon monoxide production.
N Engl J Med. 1970;282:207–209.
[PubMed: 4902834]
48. +
Coburn
RF. Carbon monoxide uptake and excretion: testing assumptions made in deriving the Coburn-Forster-Kane equation.
Respir Physiol Neurobiol. 2013;187:224–233.
[PubMed: 23602912]
49. +
Coburn
RF, Mayers
LB. Myoglobin O2 tension determined from measurement of carboxymyoglobin in skeletal muscle.
Am J Physiol. 1971;220:66–74.
[PubMed: 5538674]
50. +
Cone
DC, et al. Noninvasive fireground assessment of carboxyhemoglobin levels in firefighters.
Prehosp Emerg Care. 2005;9:8–13.
[PubMed: 16036821]
51. +
Copel
JA, et al. Carbon monoxide intoxication in early pregnancy.
Obstet Gynecol. 1982;59(6 suppl):26S–28S.
[PubMed: 7088422]
52. +
Creswell
PD, et al. Exposure to elevated carbon monoxide levels at an indoor
ice arena—Wisconsin, 2014.
MMWR Morb Mortal Wkly Rep. 2015;64:1267–1270.
[PubMed: 26583915]
53. +
Cunnington
AJ, Hormbrey
P. Breath analysis to detect recent exposure to carbon monoxide.
Postgrad Med J. 2002;78:233–237.
[PubMed: 11930027]
54. +
Damlapinar
R, et al. Lactate level is more significant than carboxihemoglobin level in determining prognosis of carbon monoxide intoxication of childhood.
Pediatr Emerg Care. 2016;32:377–383.
[PubMed: 26181501]
55. +
Davutoglu
V, et al. Serum levels of NT-ProBNP as an early cardiac marker of carbon monoxide poisoning.
Inhal Toxicol. 2006;18:155–158.
[PubMed: 16393930]
56. +
De Reuck
J, et al. A positron emission tomography study of patients with acute carbon monoxide poisoning treated by hyperbaric
oxygen.
J Neurol. 1993;240:430–434.
[PubMed: 8410085]
57. +
De Salvia
MA, et al. Irreversible impairment of active avoidance behavior in rats prenatally exposed to mild concentrations of carbon monoxide.
Psychopharmacology (Berl). 1995;122:66–71.
[PubMed: 8711066]
58. +
Denays
R, et al. Electroencephalographic mapping and 99mTc HMPAO single-photon emission computed tomography in carbon monoxide poisoning.
Ann Emerg Med. 1994;24:947–952.
[PubMed: 7978570]
59. +
Dix-Cooper
L, et al. Neurodevelopmental performance among school age children in rural Guatemala is associated with prenatal and postnatal exposure to carbon monoxide, a marker for exposure to woodsmoke.
Neurotoxicology. 2012;33:246–254.
[PubMed: 21963523]
60. +
Dogan
NO, et al. Can initial lactate levels predict the severity of unintentional carbon monoxide poisoning?
Hum Exp Toxicol. 2015;34:324–329.
[PubMed: 24972621]
61. +
Dolan
MC, et al. Carboxyhemoglobin levels in patients with flu-like symptoms.
Ann Emerg Med. 1987;16:782–786.
[PubMed: 3592333]
63. +
Ducasse
JL, et al. Non-comatose patients with acute carbon monoxide poisoning: hyperbaric or normobaric oxygenation?
Undersea Hyperb Med. 1995;22:9–15.
[PubMed: 7742714]
64. +
Eberhardt
M, et al. Noninvasive measurement of carbon monoxide levels in ED patients with headache.
J Med Toxicol. 2006;2:89–92.
[PubMed: 18072124]
65. +
Elkharrat
D, et al. Acute carbon monoxide intoxication and hyperbaric
oxygen in pregnancy.
Intensive Care Med. 1991;17:289–292.
[PubMed: 1939875]
66. +
Ely
EW, et al. Warehouse workers’ headache: emergency evaluation and management of 30 patients with carbon monoxide poisoning.
Am J Med. 1995;98:145–155.
[PubMed: 7847431]
67. +
Fawcett
TA, et al. Warehouse workers’ headache. Carbon monoxide poisoning from propane-fueled forklifts.
J Occup Med. 1992;34:12–15.
[PubMed: 1552375]
68. +
Feldman
J, et al. Treatment of carbon monoxide poisoning with hyperbaric
oxygen and therapeutic hypothermia.
Undersea Hyperb Med. 2013;40:71–79.
[PubMed: 23397870]
69. +
Fife
CEO, et al. A noninvasive method for rapid diagnosis of carbon monoxide poisoning. Intern J Emerg Intensive Care Med. 2001;5:1–8.
70. +
Gale
SD, et al. MRI, quantitative MRI, SPECT, and neuropsychological findings following carbon monoxide poisoning.
Brain Inj. 1999;13:229–243.
[PubMed: 10230524]
71. +
Garrabou
G, et al. Mitochondrial injury in human acute carbon monoxide poisoning: the effect of
oxygen treatment.
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2011;29:32–51.
[PubMed: 21424975]
72. +
Gill
JR, et al. The happy land homicides: 87 deaths due to smoke inhalation.
J Forensic Sci. 2003;48:161–163.
[PubMed: 12570219]
73. +
Gilmer
B, et al. Hyperbaric
oxygen does not prevent neurologic sequelae after carbon monoxide poisoning.
Acad Emerg Med. 2002;9:1–8.
[PubMed: 11772662]
74. +
Gilmer
BT, et al. The protective effects of experimental neurodepressors on learning and memory following carbon monoxide poisoning. J Toxicol Clin Toxicol. 1999;37:606.
75. +
Ginsberg
MD. Carbon monoxide intoxication: clinical features, neuropathology and mechanisms of injury.
J Toxicol Clin Toxicol. 1985;23:281–288.
[PubMed: 4057319]
76. +
Ginsberg
MD, Myers
RE. Fetal brain damage following maternal carbon monoxide intoxication: an experimental study.
Acta Obstet Gynecol Scand. 1974;53:309–317.
[PubMed: 4440458]
77. +
Ginsberg
MD, Myers
RE. Fetal brain injury after maternal carbon monoxide intoxication. Clinical and neuropathologic aspects.
Neurology. 1976;26:15–23.
[PubMed: 813158]
79. +
Goldbaum
LR, et al. Mechanism of the toxic action of carbon monoxide.
Ann Clin Lab Sci. 1976;6:372–376.
[PubMed: 962299]
80. +
Goldbaum
LR, et al. What is the mechanism of carbon monoxide toxicity?
Aviat Space Environ Med. 1975;46:1289–1291.
[PubMed: 1180795]
81. +
Gorman
DF, et al. A longitudinal study of 100 consecutive admissions for carbon monoxide poisoning to the Royal Adelaide Hospital.
Anaesth Intensive Care. 1992;20:311–316.
[PubMed: 1524170]
82. +
Goulon
M, et al. [Carbon monoxide poisoning and acute anoxia due to inhalation of coal gas and hydrocarbons: 302 cases, 273 treated by hyperbaric
oxygen at 2 ata].
Ann Med Interne (Paris). 1969;120:335–349.
[PubMed: 5405205]
83. +
Graber
JM, et al. Carbon monoxide: the case for environmental public health surveillance.
Public Health Rep. 2007;122:138–144.
[PubMed: 17357355]
84. +
Grabowska
T, et al. Prevalence of hydrogen cyanide and carboxyhaemoglobin in victims of smoke inhalation during enclosed-space fires: a combined toxicological risk.
Clin Toxicol (Phila). 2012;50:759–763.
[PubMed: 22882141]
85. +
Hampson
NB. Pulse oximetry in severe carbon monoxide poisoning.
Chest. 1998;114:1036–1041.
[PubMed: 9792574]
86. +
Hampson
NB. Stability of carboxyhemoglobin in stored and mailed blood samples.
Am J Emerg Med. 2008;26:191–195.
[PubMed: 18272101]
87. +
Hampson
NB. Myth busting in carbon monoxide poisoning.
Am J Emerg Med. 2016;34:295–297.
[PubMed: 26632018]
88. +
Hampson
NB. U.S. mortality due to carbon monoxide poisoning, 1999-2014. Accidental and intentional deaths.
Ann Am Thorac Soc. 2016;13:1768–1774.
[PubMed: 27466698]
90. +
Hampson
NB, et al. Symptoms of carbon monoxide poisoning do not correlate with the initial carboxyhemoglobin level.
Undersea Hyperb Med. 2012;39:657–665.
[PubMed: 22530449]
91. +
Hampson
NB, Holm
JR. Suicidal carbon monoxide poisoning has decreased with controls on automobile emissions.
Undersea Hyperb Med. 2015;42:159–164.
[PubMed: 26094291]
93. +
Hampson
NB, Little
CE. Hyperbaric treatment of patients with carbon monoxide poisoning in the United States.
Undersea Hyperb Med. 2005;32:21–26.
[PubMed: 15796311]
94. +
Hampson
NB, et al. Carbon monoxide poisoning: interpretation of randomized clinical trials and unresolved treatment issues.
Undersea Hyperb Med. 2001;28:157–164.
[PubMed: 12067152]
96. +
Hampson
NB, Weaver
LK. Carbon monoxide poisoning: a new incidence for an old disease.
Undersea Hyperb Med. 2007;34:163–168.
[PubMed: 17672172]
97. +
Hampson
NB, Zmaeff
JL. Outcome of patients experiencing cardiac arrest with carbon monoxide poisoning treated with hyperbaric
oxygen.
Ann Emerg Med. 2001;38:36–41.
[PubMed: 11423810]
98. +
Han
ST, et al. Xanthine oxidoreductase and neurological sequelae of carbon monoxide poisoning.
Toxicol Lett. 2007;170:111–115.
[PubMed: 17433579]
99. +
Health. National Institute for Occupational Safety and Health. NIOSH Pocket Guide to Chemical Hazards. In: Department of Health and Human Services Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, ed. Vol DHHS Publication No. 2005-149. Washington, DC: U.S. Government Printing Offices; 2007.
100. +
Heckerling
PS, et al. Occult carbon monoxide poisoning: validation of a prediction model.
Am J Med. 1988;84:251–256.
[PubMed: 3407653]
101. +
Heckerling
PS, et al. Predictors of occult carbon monoxide poisoning in patients with headache and dizziness.
Ann Intern Med. 1987;107:174–176.
[PubMed: 3605895]
103. +
Hill
EP, et al. Carbon monoxide exchanges between the human fetus and mother: a mathematical model.
Am J Physiol. 1977;232:H311–323.
[PubMed: 842687]
104. +
Hirsch
AE, et al. Carbon monoxide poisonings from forklift use during produce packing operations. J Agromed. 2016;21:132–135.
105. +
Hopkins
RO, et al. Basal ganglia lesions following carbon monoxide poisoning.
Brain Inj. 2006;20:273–281.
[PubMed: 16537269]
106. +
Hopkins
RO, et al. Apolipoprotein E genotype and response of carbon monoxide poisoning to hyperbaric
oxygen treatment.
Am J Respir Crit Care Med. 2007;176:1001–1006.
[PubMed: 17702967]
107. +
Hou
X, et al. Diffusion tensor imaging for predicting the clinical outcome of delayed encephalopathy of acute carbon monoxide poisoning.
Eur Neurol. 2013;69:275–280.
[PubMed: 23429164]
108. +
Huang
CC, et al. Hyperbaric
oxygen therapy is associated with lower short- and long-term mortality in patients with carbon monoxide poisoning.
Chest. 2017;152:943–953.
[PubMed: 28427969]
109. +
Hullin
T, et al. Correlation between clinical severity and different non-invasive measurements of carbon monoxide concentration: a population study.
PloS One. 2017;12:e0174672.
[PubMed: 28350859]
110. +
Ide
T, et al. Elevated S100B level in cerebrospinal fluid could predict poor outcome of carbon monoxide poisoning.
Am J Emerg Med. 2012;30:222–225.
[PubMed: 21185668]
111. +
Iqbal
S, et al. Carbon monoxide-related hospitalizations in the U.S.: evaluation of a web-based query system for public health surveillance.
Public Health Rep. 2010;125:423–432.
[PubMed: 20433037]
112. +
Iqbal
S, et al. Hospital burden of unintentional carbon monoxide poisoning in the United States, 2007.
Am J Emerg Med. 2012;30:657–664.
[PubMed: 21570230]
113. +
Ishimaru
H, et al. Effects of N-methyl-D-aspartate receptor antagonists on carbon monoxide-induced brain damage in mice.
J Pharmacol Exp Ther. 1992;261:349–352.
[PubMed: 1532836]
114. +
Jackson
EB Jr, et al. Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system—from bench top to bedside.
Curr Vasc Pharmacol. 2007;5:1–14.
[PubMed: 17266609]
115. +
Johnson-Arbor
KK, et al. A comparison of carbon monoxide exposures after snowstorms and power outages.
Am J Prev Med. 2014;46:481–486.
[PubMed: 24745638]
116. +
Jung
YS, et al. Carbon monoxide-induced cardiomyopathy.
Circ J. 2014;78:1437–1444.
[PubMed: 24705389]
117. +
Juric
DM, et al. Hyperbaric
oxygen preserves neurotrophic activity of carbon monoxide-exposed astrocytes.
Toxicol Lett. 2016;253:1–6.
[PubMed: 27113706]
118. +
Kalay
N, et al. Cardiovascular effects of carbon monoxide poisoning.
Am J Cardiol. 2007;99:322–324.
[PubMed: 17261390]
119. +
Karaman
D, et al. Neuropsychological evaluation of children and adolescents with acute carbon monoxide poisoning.
Pediatr Emerg Care. 2016;32:303–306.
[PubMed: 26011807]
121. +
Klasner
AE, et al. Carbon monoxide mass exposure in a pediatric population.
Acad Emerg Med. 1998;5:992–996.
[PubMed: 9862591]
122. +
Koren
G, et al. A multicenter, prospective study of fetal outcome following accidental carbon monoxide poisoning in pregnancy.
Reprod Toxicol. 1991;5:397–403.
[PubMed: 1806148]
123. +
Krantz
T, et al. Acute carbon monoxide poisoning.
Acta Anaesthesiol Scand. 1988;32:278–282.
[PubMed: 3394478]
124. +
Krenzelok
EP, et al. Carbon monoxide … the silent killer with an audible solution.
Am J Emerg Med. 1996;14:484–486.
[PubMed: 8765117]
125. +
Kunsman
GW, et al. Carbon monoxide stability in stored postmortem blood samples.
J Anal Toxicol. 2000;24:572–578.
[PubMed: 11043662]
126. +
Kuroda
H, et al. Altered white matter metabolism in delayed neurologic sequelae after carbon monoxide poisoning: a proton magnetic resonance spectroscopic study.
J Neurol Sci. 2016;360:161–169.
[PubMed: 26723994]
127. +
Kurt
F, et al. Does age affect presenting symptoms in children with carbon monoxide poisoning?
Pediatr Emerg Care. 2013;29:916–921.
[PubMed: 23903672]
128. +
Lacey
DJ. Neurologic sequelae of acute carbon monoxide intoxication.
Am J Dis Child. 1981;135:145–147.
[PubMed: 7468546]
129. +
Lapresle
J, Fardeau
M. The central nervous system and carbon monoxide poisoning. II. Anatomical study of brain lesions following intoxication with carbon monoxide (22 cases).
Prog Brain Res. 1967;24:31–74.
[PubMed: 6075035]
130. +
LaSala
G, et al. The epidemiology and characteristics of carbon monoxide poisoning among recreational boaters.
Clin Toxicol (Phila). 2015;53:127–130.
[PubMed: 25567686]
131. +
Lee
FY, et al. Carbon monoxide poisoning and subsequent cardiovascular disease risk: a nationwide population-based cohort study.
Medicine. 2015;94:e624.
[PubMed: 25761191]
132. +
Lee
JH, et al. Incidence and clinical course of left ventricular systolic dysfunction in patients with carbon monoxide poisoning.
Korean Circ J. 2016;46:665–671.
[PubMed: 27721858]
133. +
Lee
MS, Marsden
CD. Neurological sequelae following carbon monoxide poisoning clinical course and outcome according to the clinical types and brain computed tomography scan findings.
Mov Disord. 1994;9:550–558.
[PubMed: 7990850]
134. +
Leikin
JB, et al. Methylene chloride: report of five exposures and two deaths.
Am J Emerg Med. 1990;8:534–537.
[PubMed: 2222600]
135. +
Levasseur
L, et al. Effects of mode of inhalation of carbon monoxide and of normobaric
oxygen administration on carbon monoxide elimination from the blood.
Hum Exp Toxicol. 1996;15:898–903.
[PubMed: 8938485]
137. +
Lo
CP, et al. Brain injury after acute carbon monoxide poisoning: early and late complications.
AJR Am J Roentgenol. 2007;189:W205–211.
[PubMed: 17885032]
138. +
Logue
CJ. An inconvenient truth?
Ann Emerg Med. 2008;51:339–340; author reply 340-332.
[PubMed: 18282535]
139. +
Longo
LD. Carbon monoxide in the pregnant mother and fetus and its exchange across the placenta.
Ann N Y Acad Sci. 1970;174:312–341.
[PubMed: 4943972]
140. +
Longo
LD, Hill
EP. Carbon monoxide uptake and elimination in fetal and maternal sheep.
Am J Physiol. 1977;232:H324–330.
[PubMed: 842688]
141. +
Mannaioni
PF, et al. Carbon monoxide: the bad and the good side of the coin, from neuronal death to anti-inflammatory activity.
Inflamm Res. 2006;55:261–273.
[PubMed: 16955388]
142. +
Mathieu
D, et al. Acute carbon monoxide poisoning. Risk of late sequelae and treatment by hyperbaric
oxygen.
J Toxicol Clin Toxicol. 1985;23:315–324.
[PubMed: 4057322]
143. +
Mathieu
D, et al. Randomized prospective study comparing the effect of HBO versus 12 hours of NBO in non comatose CO poisoned patients: results of the interim analysis.
Undersea Hyperb Med. 1996;23(suppl):7–8.
[PubMed: 8939267]
144. +
McNulty
JA, et al. Relationship of short-term verbal memory to the need for hyperbaric
oxygen treatment after carbon monoxide poisoning.
Neuropsychiatry Neuropsychol Behav Neurol. 1997;10:174–179.
[PubMed: 9297710]
145. +
Messier
LD, Myers
RA. A neuropsychological screening battery for emergency assessment of carbon-monoxide-poisoned patients.
J Clin Psychol. 1991;47:675–684.
[PubMed: 1939714]
146. +
Miro
O, et al. Oxidative damage on lymphocyte membranes is increased in patients suffering from acute carbon monoxide poisoning.
Toxicol Lett. 1999;110:219–223.
[PubMed: 10597031]
147. +
Miro
O, et al. Mitochondrial cytochrome c oxidase inhibition during acute carbon monoxide poisoning.
Pharmacol Toxicol. 1998;82:199–202.
[PubMed: 9584335]
148. +
Miura
T, et al. CT of the brain in acute carbon monoxide intoxication: characteristic features and prognosis.
AJNR Am J Neuroradiol. 1985;6:739–742.
[PubMed: 3933295]
149. +
Molzhaninov
EVC, et al. Experience and prospects of using hyperbaric oxygenation in obstetrics. Paper presented at Proceedings of the 7th International Congress on Hyperbaric Medicine, Moscow; 1981.
150. +
Moon
JM, et al. The value of initial lactate in patients with carbon monoxide intoxication: in the emergency department.
Hum Exp Toxicol. 2011;30:836–843.
[PubMed: 20876159]
152. +
Myers
RA, Britten
JS. Are arterial blood gases of value in treatment decisions for carbon monoxide poisoning?
Crit Care Med. 1989;17:139–142.
[PubMed: 2644066]
153. +
Myers
RA, et al. Chronic carbon monoxide exposure: a clinical syndrome detected by neuropsychological tests.
J Clin Psychol. 1998;54:555–567.
[PubMed: 9696105]
154. +
Myers
RA, et al. Subacute sequelae of carbon monoxide poisoning.
Ann Emerg Med. 1985;14:1163–1167.
[PubMed: 4061987]
155. +
Myers
RAJ, et al. Carbon monoxide half-life study. Paper presented at: Proceedings of the 9th International Congress on Hyperbaric Medicine, Flagstaff, AZ; 1987.
156. +
Nager
EC, O’Connor
RE. Carbon monoxide poisoning from spray paint inhalation.
Acad Emerg Med. 1998;5:84–86.
[PubMed: 9444350]
157. +
Norkool
DM, Kirkpatrick
JN. Treatment of acute carbon monoxide poisoning with hyperbaric
oxygen: a review of 115 cases.
Ann Emerg Med. 1985;14:1168–1171.
[PubMed: 4061988]
158. +
Oh
BJ, et al. Treatment of acute carbon monoxide poisoning with induced hypothermia.
Clin Exp Emerg Med. 2016;3:100–104.
[PubMed: 27752625]
159. +
Okeda
R, et al. Comparative study on pathogenesis of selective cerebral lesions in carbon monoxide poisoning and nitrogen hypoxia in cats.
Acta Neuropathol. 1982;56:265–272.
[PubMed: 7090735]
160. +
Okeda
R, et al. The pathogenesis of carbon monoxide encephalopathy in the acute phase—physiological and morphological correlation.
Acta Neuropathol. 1981;54:1–10.
[PubMed: 7234325]
161. +
Otten
EJ, et al. An evaluation of carboxyhemoglobin spot tests.
Ann Emerg Med. 1985;14:850–852.
[PubMed: 4025981]
162. +
Ozyurt
A, et al. Effects of acute carbon monoxide poisoning on ECG and echocardiographic parameters in children.
Cardiovasc Toxicol. 2017;17:326–334.
[PubMed: 27778147]
163. +
Ozyurt
G, et al. Comparison of SPECT findings and neuropsychological sequelae in carbon monoxide and organophosphate poisoning.
Clin Toxicol (Phila). 2008;46:218–221.
[PubMed: 18344103]
164. +
Pace
R, et al. Effects of
hydroxocobalamin on carboxyhemoglobin measured under physiologic and pathologic conditions.
Clin Toxicol (Phila). 2014;52:647–650.
[PubMed: 25089720]
165. +
Pang
L, et al. Neuroprotective effects of erythropoietin in patients with carbon monoxide poisoning.
J Biochem Mol Toxicol. 2013;27:266–271.
[PubMed: 23554277]
166. +
Pang
L, et al. Erythropoietin protects rat brain injury from carbon monoxide poisoning by inhibiting Toll-like receptor 4/NF-kappa B-dependent inflammatory responses.
Inflammation. 2016;39:561–568.
[PubMed: 26521252]
167. +
Parkinson
RB, et al. White matter hyperintensities and neuropsychological outcome following carbon monoxide poisoning.
Neurology. 2002;58:1525–1532.
[PubMed: 12034791]
168. +
Penney
DG. Acute carbon monoxide poisoning in an animal model: the effects of altered glucose on morbidity and mortality.
Toxicology. 1993;80:85–101.
[PubMed: 8328003]
169. +
Penney
DG, Chen
K. NMDA receptor-blocker
ketamine protects during acute carbon monoxide poisoning, while calcium channel-blocker
verapamil does not.
J Appl Toxicol. 1996;16:297–304.
[PubMed: 8854215]
170. +
Pepe
G, et al. Delayed neuropsychological sequelae after carbon monoxide poisoning: predictive risk factors in the Emergency Department. A retrospective study.
Scand J Trauma Resusc Emerg Med. 2011;19:16.
[PubMed: 21414211]
171. +
Peterson
JE, Stewart
RD. Absorption and elimination of carbon monoxide by inactive young men.
Arch Environ Health. 1970;21:165–171.
[PubMed: 5430002]
172. +
Piantadosi
CA, et al. Apoptosis and delayed neuronal damage after carbon monoxide poisoning in the rat.
Exp Neurol. 1997;147:103–114.
[PubMed: 9294407]
173. +
Porter
SS, et al. Corpus callosum atrophy and neuropsychological outcome following carbon monoxide poisoning.
Arch Clin Neuropsychol. 2002;17:195–204.
[PubMed: 14589748]
174. +
Raphael
JC, et al. Trial of normobaric and hyperbaric
oxygen for acute carbon monoxide intoxication.
Lancet. 1989;2:414–419.
[PubMed: 2569600]
175. +
Rasmussen
LS, et al. Biochemical markers for brain damage after carbon monoxide poisoning.
Acta Anaesthesiol Scand. 2004;48:469–473.
[PubMed: 15025610]
176. +
Ratney
RS, et al. In vivo conversion of methylene chloride to carbon monoxide.
Arch Environ Health. 1974;28:223–226.
[PubMed: 4814958]
177. +
Rioux
JP, Myers
RA. Hyperbaric
oxygen for methylene chloride poisoning: report on two cases.
Ann Emerg Med. 1989;18:691–695.
[PubMed: 2729697]
178. +
Risser
D, et al. Should coroners be able to recognize unintentional carbon monoxide-related deaths immediately at the death scene?
J Forensic Sci. 1995;40:596–598.
[PubMed: 7595295]
179. +
Roth
D, et al. Accuracy of noninvasive multiwave pulse oximetry compared with carboxyhemoglobin from blood gas analysis in unselected emergency department patients.
Ann Emerg Med. 2011;58:74–79.
[PubMed: 21459480]
180. +
Roughton
FJWD. The effect of carbon monoxide on the oxyhemoglobin dissociation curve. Am J Physiol. 1944;141:17–31.
181. +
Sanders
RW, et al. Seizure during hyperbaric
oxygen therapy for carbon monoxide toxicity: a case series and five-year experience.
J Emerg Med. 2012;42:e69–72.
[PubMed: 19372022]
182. +
Scheinkestel
CD, et al. Hyperbaric or normobaric
oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial.
Med J Aust. 1999;170:203–210.
[PubMed: 10092916]
183. +
Sebbane
M, et al. Emergency department management of suspected carbon monoxide poisoning: role of pulse CO-oximetry.
Respir Care. 2013;58:1614–1620.
[PubMed: 23513247]
184. +
Shapiro
AB, et al. Carbon monoxide and myonecrosis: a prospective study.
Vet Hum Toxicol. 1989;31:136–137.
[PubMed: 2929121]
185. +
Shimazu
T, et al. Smoke inhalation injury and the effect of carbon monoxide in the sheep model.
J Trauma. 1990;30:170–175.
[PubMed: 2304110]
186. +
Shusterman
D, et al. Predictors of carbon monoxide and hydrogen cyanide exposure in smoke inhalation patients.
J Toxicol Clin Toxicol. 1996;34:61–71.
[PubMed: 8632515]
187. +
Sircar
K, et al. Carbon monoxide poisoning deaths in the United States, 1999 to 2012.
Am J Emerg Med. 2015;33:1140–1145.
[PubMed: 26032660]
188. +
Sloan
EP, et al. Complications and protocol considerations in carbon monoxide-poisoned patients who require hyperbaric
oxygen therapy: report from a ten-year experience.
Ann Emerg Med. 1989;18:629–634.
[PubMed: 2729687]
189. +
Sokal
JA, Kralkowska
E. The relationship between exposure duration, carboxyhemoglobin, blood glucose, pyruvate and lactate and the severity of intoxication in 39 cases of acute carbon monoxide poisoning in man.
Arch Toxicol. 1985;57:196–199.
[PubMed: 4062554]
192. +
Stewart
RD, et al. Experimental human exposure to high concentrations of carbon monoxide.
Arch Environ Health. 1973;26:1–7.
[PubMed: 4682844]
193. +
Suner
S, et al. Non-invasive pulse CO-oximetry screening in the emergency department identifies occult carbon monoxide toxicity.
J Emerg Med. 2008;34:441–450.
[PubMed: 18226877]
194. +
Sutariya
BB, et al. Hypothermia following acute carbon-monoxide poisoning increases mortality.
Toxicol Lett. 1990;52:201–208.
[PubMed: 2378003]
195. +
Takeuchi
A, et al. A simple “new” method to accelerate clearance of carbon monoxide.
Am J Respir Crit Care Med. 2000;161:1816–1819.
[PubMed: 10852750]
196. +
Taskiran
D, et al. Mitochondrial oxidative stress in female and male rat brain after ex vivo carbon monoxide treatment.
Hum Exp Toxicol. 2007;26:645–651.
[PubMed: 17884952]
197. +
Teksam
M, et al. Diffusion-weighted MR imaging findings in carbon monoxide poisoning.
Neuroradiology. 2002;44:109–113.
[PubMed: 11942360]
198. +
Teksam
O, et al. Acute cardiac effects of carbon monoxide poisoning in children.
Eur J Emerg Med. 2010;17:192–196.
[PubMed: 20195157]
199. +
Thom
SR. Carbon monoxide-mediated brain lipid peroxidation in the rat.
J Appl Physiol (1985). 1990;68:997–1003.
[PubMed: 2341364]
200. +
Thom
SR. Dehydrogenase conversion to oxidase and lipid peroxidation in brain after carbon monoxide poisoning.
J Appl Physiol (1985). 1992;73:1584–1589.
[PubMed: 1447108]
201. +
Thom
SR. Leukocytes in carbon monoxide-mediated brain oxidative injury.
Toxicol Appl Pharmacol. 1993;123:234–247.
[PubMed: 8248931]
202. +
Thom
SR, et al. Delayed neuropathology after carbon monoxide poisoning is immune-mediated.
Proc Natl Acad Sci U S A. 2004;101:13660–13665.
[PubMed: 15342916]
203. +
Thom
SR, et al. Intravascular neutrophil activation due to carbon monoxide poisoning.
Am J Respir Crit Care Med. 2006;174:1239–1248.
[PubMed: 16931637]
204. +
Thom
SR, et al. Plasma biomarkers in carbon monoxide poisoning.
Clin Toxicol (Phila). 2010;48:47–56.
[PubMed: 20095814]
205. +
Thom
SR, et al. Role of nitric oxide-derived oxidants in vascular injury from carbon monoxide in the rat.
Am J Physiol. 1999;276(3 Pt 2):H984–992.
[PubMed: 10070083]
206. +
Thom
SR, et al. Adaptive responses and apoptosis in endothelial cells exposed to carbon monoxide.
Proc Natl Acad Sci U S A. 2000;97:1305–1310.
[PubMed: 10655526]
207. +
Thom
SR, et al. Neuronal nitric oxide synthase and N-methyl-D-aspartate neurons in experimental carbon monoxide poisoning.
Toxicol Appl Pharmacol. 2004;194:280–295.
[PubMed: 14761684]
208. +
Thom
SR, et al. Release of glutathione from erythrocytes and other markers of oxidative stress in carbon monoxide poisoning.
J Appl Physiol (1985). 1997;82:1424–1432.
[PubMed: 9134888]
209. +
Thom
SR, Keim
LW. Carbon monoxide poisoning: a review epidemiology, pathophysiology, clinical findings, and treatment options including hyperbaric
oxygen therapy.
J Toxicol Clin Toxicol. 1989;27:141–156.
[PubMed: 2681810]
210. +
Thom
SR, et al. Inhibition of human neutrophil beta2-integrin-dependent adherence by hyperbaric O2.
Am J Physiol. 1997;272(3 Pt 1):C770–777.
[PubMed: 9124510]
211. +
Thom
SR, et al. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric
oxygen.
Ann Emerg Med. 1995;25:474–480.
[PubMed: 7710151]
212. +
Tikuisis
P. Modeling the uptake and elimination of carbon monoxide. In: Penney
DG, ed. Carbon Monoxide. Boca Raton, FL: CRC Press; 1996:45–67.
213. +
Tom
T, et al. Neuroimaging characteristics in carbon monoxide toxicity.
J Neuroimaging. 1996;6:161–166.
[PubMed: 8704291]
214. +
Touger
M, et al. Performance of the RAD-57 pulse CO-oximeter compared with standard laboratory carboxyhemoglobin measurement.
Ann Emerg Med. 2010;56:382–388.
[PubMed: 20605259]
215. +
Tsai
CF, et al. The impacts of acute carbon monoxide poisoning on the brain: longitudinal clinical and 99mTc ethyl cysteinate brain SPECT characterization of patients with persistent and delayed neurological sequelae.
Clin Neurol Neurosurg. 2014;119:21–27.
[PubMed: 24635920]
216. +
Turner
M, et al. Carbon monoxide poisoning treated with hyperbaric
oxygen: metabolic acidosis as a predictor of treatment requirements.
J Accid Emerg Med. 1999;16:96–98.
[PubMed: 10191440]
218. +
Van Sickle
D, et al. Carbon monoxide poisoning in Florida during the 2004 hurricane season.
Am J Prev Med. 2007;32:340–346.
[PubMed: 17383566]
219. +
Vreman
HJ, et al. Carbon monoxide and carboxyhemoglobin.
Adv Pediatr. 1995;42:303–334.
[PubMed: 8540431]
220. +
Vreman
HJ, et al. Interference of fetal hemoglobin with the spectrophotometric measurement of carboxyhemoglobin.
Clin Chem. 1988;34:975–977.
[PubMed: 2453310]
221. +
Watanabe
S, et al. Transient degradation of myelin basic protein in the rat hippocampus following acute carbon monoxide poisoning.
Neurosci Res. 2010;68:232–240.
[PubMed: 20633582]
222. +
Wattel
F, et al. [A 25-year study (1983-2008) of children’s health outcomes after hyperbaric
oxygen therapy for carbon monoxide poisoning in utero].
Bull Acad Natl Med. 2013;197:677–694; discussion 695-677.
[PubMed: 25163349]
223. +
Weaver
LK. Clinical practice. Carbon monoxide poisoning.
N Engl J Med. 2009;360:1217–1225.
[PubMed: 19297574]
224. +
Weaver
LK. Carbon monoxide poisoning. In: Weaver
LK, ed.
Hyperbaric Oxygen Therapy Indications. North Palm Beach, FL: Best Publishing Company; 2014:47–66.
225. +
Weaver
LK, Deru
K. Carbon monoxide poisoning at motels, hotels, and resorts.
Am J Prev Med. 2007;33:23–27.
[PubMed: 17572307]
226. +
Weaver
LK, et al. Hyperbaric
oxygen for acute carbon monoxide poisoning.
N Engl J Med. 2002;347:1057–1067.
[PubMed: 12362006]
227. +
Weaver
LK, et al. Carboxyhemoglobin half-life in carbon monoxide-poisoned patients treated with 100%
oxygen at atmospheric pressure.
Chest. 2000;117:801–808.
[PubMed: 10713010]
228. +
Weaver
LK, et al. Carbon monoxide poisoning: risk factors for cognitive sequelae and the role of hyperbaric
oxygen.
Am J Respir Crit Care Med. 2007;176:491–497.
[PubMed: 17496229]
229. +
Westphal
M, et al. Affinity of carbon monoxide to hemoglobin increases at low
oxygen fractions.
Biochem Biophys Res Commun. 2002;295:975–977.
[PubMed: 12127991]
230. +
Widdop
B. Analysis of carbon monoxide.
Ann Clin Biochem. 2002;39(Pt 4):378–391.
[PubMed: 12117442]
231. +
Wolf
SJ, et al. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with acute carbon monoxide poisoning.
J Emerg Nurs. 2008;34:e19–32.
[PubMed: 18358340]
232. +
Wolf
SJ, et al. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute carbon monoxide poisoning.
Ann Emerg Med. 2017;69:98–107.e106.
[PubMed: 27993310]
233. +
Wong
CS, et al. Increased Long-term risk of dementia in patients with carbon monoxide poisoning: a population-based study.
Medicine. 2016;95:e2549.
[PubMed: 26817904]
234. +
Wrenn
K, Conners
GP. Carbon monoxide poisoning during
ice storms: a tale of two cities.
J Emerg Med. 1997;15:465–467.
[PubMed: 9279696]
235. +
Xiang
W, et al. Combined application of
dexamethasone and hyperbaric
oxygen therapy yields better efficacy for patients with delayed encephalopathy after acute carbon monoxide poisoning.
Drug Design Devel Ther. 2017;11:513–519.
236. +
Xiang
W, et al. Efficacy of N-butylphthalide and hyperbaric
oxygen therapy on cognitive dysfunction in patients with delayed encephalopathy after acute carbon monoxide poisoning.
Med Sci Monit. 2017;23:1501–1506.
[PubMed: 28352069]
237. +
Xu
J, et al. Carbon monoxide inhalation increases microparticles causing vascular and CNS dysfunction.
Toxicol Appl Pharmacol. 2013;273:410–417.
[PubMed: 24090814]
238. +
Yarar
C, et al. Analysis of the features of acute carbon monoxide poisoning and hyperbaric
oxygen therapy in children.
Turk J Pediatr. 2008;50:235–241.
[PubMed: 18773668]
239. +
Yoshii
F, et al. Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning.
J Neurol Sci. 1998;160:87–91.
[PubMed: 9804123]
240. +
Zeiss
J, Brinker
R. Role of contrast enhancement in cerebral CT of carbon monoxide poisoning.
J Comput Assist Tomogr. 1988;12:341–343.
[PubMed: 3351054]
241. +
Ziser
A, et al. Delayed hyperbaric
oxygen treatment for acute carbon monoxide poisoning.
Br Med J (Clin Res Ed). 1984;289:960.
[PubMed: 6435739]